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Placebo comparisons are increasingly being considered for randomised trials assessing the efficacy 
of surgical interventions. The aim of this paper is to provide a summary of current knowledge on 
placebo controls in surgical trials. 
A placebo control is a complex type of comparison group and, although powerful, presents many 
challenges in a surgical setting. This review outlines what a placebo-surgical control entails and our 
understanding of the placebo phenomenon in the context of surgery. It considers when placebo-
surgical controls are acceptable (and when they are desirable) in terms of ethical arguments and 
regulatory requirements, how a placebo-surgical control should be designed, how to identify and 
mitigate risk for participants in placebo surgical trials, how such trials should be conducted and 
interpreted. 
Use of placebo control is justified in randomised controlled trials of surgical interventions provided 
there is a strong scientific and ethical rationale. Surgical placebos may be most appropriate where 
there is poor evidence on the efficacy of the procedure and a justified concern that results of a trial 
would be associated with high risk of bias, particularly due to the placebo effect. Feasibility work is 
recommended to optimise RCT design and conduct. This review forms an outline for best practice 
and provides guidance, in the form of the ASPIRE (Applying Surgical Placebo in Randomised 
Evaluations) checklist, for those considering the use of a placebo-control in a surgical randomised 
controlled trial. 
INTRODUCTION & BACKGROUND 
Compelling evidence of efficacy and safety should underpin all routine clinical therapies, ideally 
based on data from randomised controlled trials (RCT), and surgical therapies are no exception. 
Whilst an RCT comparing surgical treatment to no surgical treatment provides evidence of overall 
efficacy, it fails to account for certain biases, especially placebo. These potential biases are 
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particularly high for surgical interventions, where placebo effects have been shown to have 
substantial magnitude and duration, often amplified by the particular context of surgical care 1,2. A 
surgical placebo control can be used to minimise bias but its use can be controversial as it poses 
potential risk to the patient with reduced potential benefit and presents ethical, design and trial 
conduct challenges. 
Previous reviews have been conducted of placebo-controlled surgical trials 2-4 including their use, 
issues of recruitment and feasibility, and impact on outcome and serious adverse events 5,6. These 
reviews have not, however, explicitly considered issues of trial design such as definition and content 
of placebo, when it is appropriate to use (or not use) a placebo control in a surgical trial, what 
factors should guide the choice of a placebo design and how that choice influences intervention 
standardisation. Some information on the ethical implications of surgical placebo trials is available 7-
12. 
This review aims to provide state of the art knowledge on all aspects of placebo controls in 
evaluation of surgery. The insights are primarily based on the outputs of a workshop funded by the 
UK’s National Institute of Health Research and Medical Research Council which brought together an 
international team of interdisciplinary experts with a strong track record of research in this field. The 
workshop included a systematic update of salient literature, in depth discussion of case studies and 
exposition of direct experience and best practice. The work culminated in the production of practical 
guidance for researchers; the ASPIRE (Applying Surgical Placebo in Randomised Evaluations) 
checklist. We have restricted our focus to studies of adults with capacity to consent to participate in 
surgical research. 
WHAT IS A “PLACEBO” IN THE CONTEXT OF SURGICAL TRIALS 
Understanding the placebo phenomenon 
Placebo effect knowledge is dominated by two main psychological theories, both of which apply to 
surgery. These are broadly labelled: 1) “conditioning”, a learning theory in which placebo effects are 
underpinned by associative learning with the placebo paired with an active treatment to trigger a 
physiological response; and 2) “response expectancy”, where the placebo effects are underpinned 
by the patient’s conscious or unconscious expectation that the placebo will have a particular effect 
13. Colloca and Miller integrated the learning and response expectancy theories to suggest that 
patient expectations are the central psychological mechanism that mediate placebo effects 14. 
According to this model, the brain decodes the psychosocial context, formulating (conscious or 
unconscious) expectations about outcome that then trigger placebo responses. In turn these 
expectations are shaped by learning mechanisms around three types of “signs” (signs are things that 
convey specific meanings to individuals) in the psychosocial context 15: 1) indices which generate 
expectations through sensory or memory-based associations for individuals; in essence a 
conditioned response 16; 2) symbols, which generate expectations through culturally-specific 
conventions including language, ritual and doctor-patient communication 17; and 3) icons which 
generate expectations through perceived similarities with the object, in short, expectations through 
social learning mechanisms 18. 
The manner in which patients are informed about the placebo control also shapes patients’ 
expectations. Any imbalance in the tone and quantity of information given about the benefits of the 




Further work has characterised how different domains of the psychosocial context of healthcare are 
at play in clinical trials and may influence the response to a surgical placebo. These key domains 
include the treatment characteristics; the healthcare setting; clinician characteristics; patient 
characteristics; and the patient-clinician interaction. Examples of the ways that they may influence 
the placebo response is presented in Table 1. 20,21  With regard to the placebo response in general, it 
should also be noted that there is some suggestion of genetic susceptibility to placebo with 
biomarkers indicating at least a moderate influence of genes on placebo response22. Furthermore, a 
largely unexplored aspect of placebo is the geographic and cultural differences in patients that could 
influence a response. Both such factors would apply to surgical placebos similarly to that of 
pharmaceutical placebo but would also apply equally across groups in a randomised design. 
Definition of a surgical placebo 
In this paper, surgery is defined as an invasive procedure using any access to the body (incision, 
natural orifice or percutaneous), includes use of instrumentation and operator skill 23. One important 
distinction to highlight is between the concept of placebo for evaluation purposes, as in an 
experimental placebo control (as described in this paper), and the notion of purposely using placebo 
for benefit or treatment. 
A clear definition of experimental placebo is lacking for surgical trials and classical definitions can 
introduce conceptual confusion rather than clarity. The blurred lines for surgical placebo are 
epitomised by the various descriptions in the literature. These vary from “a surgical intervention 
with theoretically little benefit”5 to “sham” surgery (entirely simulated surgery or small superficial 
incision only)24 to a “placebo surgical intervention”, a procedure in which presumed “active” 
components of the procedure or the critical surgical element have been removed 25. In the latter, the 
“placebo surgical intervention” consists of routine delivery of most of the operation, but with 
exclusion of the presumptive “active component”. However, identification of, and conceptual clarity 
in defining the “critical surgical element” in surgery can be far from straightforward. 
Rather than using the all-encompassing and generic “placebo control” to describe any form of 
placebo content, greater clarity can be achieved by describing the placebo control in terms of its 
fidelity or proximity to the complete surgical procedure 26. Varying levels of fidelity are possible from 
minimal fidelity, in which there is little similarity to the complete surgical intervention (i.e. skin 
incisions only, thus resembling what surgeons would have traditionally described as a “sham” 
treatment) all the way to treatment with a complete set of surgical attributes, viz. maximum fidelity 
(i.e. the surgical procedure under evaluation). In between these extremes a high fidelity placebo may 
have identical surgical content and attributes to the complete surgical procedure but solely without 
the presumed active or critical component. A low fidelity placebo may have fewer surgical 
components and less resemble the complete surgical procedure (Table 2). 
For example when evaluating the efficacy of arthroscopic subacromial decompression of the 
shoulder various choices for the placebo control exist. Maximum fidelity is the complete 
decompression surgery; a high fidelity placebo may be identical surgery but without removal of bone 
only; a low fidelity placebo may be very similar surgery but without removal of bone/soft tissue and 
lacking some other operative procedures i.e. just the insertion of an arthroscope; and a minimum 
fidelity treatment being surgical skin incisions only. Similarly, in a study of endoscopic 
radiofrequency ablation in patients with dysplastic Barrett’s esophagus the normal or maximum 
fidelity intervention involved ablation using a catheter. Patients randomised to the placebo 
intervention group underwent a lower fidelity procedure involving upper endoscopy, esophageal 
intubation and measurement of esophageal inner diameter only.27 
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It should be noted that this working framework is dependent on the theoretical premises of the 
operation and postulation of a “critical surgical element”.  This is not always possible, especially with 
surgeries that create effect by a multi-modal or dependent set of procedures. 
WHEN ARE PLACEBO-SURGICAL CONTROLS ACCEPTABLE?  
Surgical placebos may be most appropriate where there is poor evidence on the efficacy of the 
procedure and a justified concern that the results of an open trial would be associated with high risk 
of bias. 
Ethical considerations are fundamental to the decision as to whether one can use a surgical placebo 
control. Patients participating in a placebo controlled surgical trial are exposed to the risks of a 
surgical intervention that lacks the presumptive causally effective element (i.e. the critical surgical 
element). Participants are, therefore, potentially being exposed to some of the risks of surgery with 
less of the perceived benefits. Ethical standards suggest, however, that exposing research 
participants to such risks is allowed provided equipoise exists among the study arms, study harms 
have been minimised and are acceptable to the participant 28,29. 
The use of a placebo control in a surgical RCT is consistent with the ethical principle of beneficence 
provided the benefits and harms posed are reasonable and risks are offset by the social value of the 
study 7. One way to determine whether the benefits and harms of a trial are acceptable is to perform 
component analysis 30. In component analysis, a trial’s therapeutic procedures must be considered 
separately from its nontherapeutic procedures. However, in surgical placebos this separation is not 
straightforward as a placebo intervention lacking the critical surgical element may nonetheless 
induce physiological changes in the patient. Thus, we distinguish between the placebo control that 
includes warranted therapeutic procedures, in which the prospect of direct patient benefit is 
supported by evidence, and nontherapeutic procedures, in which no such warrant exists and the 
procedure is conducted for scientific purposes. 
The analysis of benefits and harms in placebo controlled surgical trials is further complicated by the 
fact that the placebo control includes both warranted therapeutic and nontherapeutic procedures. 
To address this, a two-step ethical analysis is required. First, one must consider whether the use of 
any placebo control is justified i.e. whether equipoise holds in the face of a placebo control. 
Equipoise is defined as “a state of disagreement or uncertainty in the informed, expert medical 
community about the relative clinical merits of the intervention arms in a trial” 31. Disagreement or 
uncertainty should be understood in terms of the state of evidence rather than unsubstantiated 
opinion. If equipoise exists, then it does not matter to the surgeon which trial arm the participant is 
placed into; given the state of knowledge at the beginning of the trial, both arms are deemed to be 
broadly consistent with competent surgical care 30. A placebo control is permissible to evaluate a 
novel surgical procedure in a condition for which there is no proven, effective surgical intervention. 
Additionally, the case for placebo control design for surgery becomes stronger when the evidence 
base supporting a procedure in common use is poor, such as for vertebroplasty 32. Although the 
surgical procedure is commonly used, equipoise exists because of the lack of supporting evidence.32 
Thus, in both cases, the use of a placebo control is consistent with equipoise because there is 
sufficient uncertainty over whether surgery offers any advantage over non surgical management 
alone. 
If placebo is justified, then the appropriate level of fidelity to the surgical intervention must then be 
considered. To make this determination, two standards are relevant 30. First, the harms posed by the 
intervention must be minimized. Second, the risks posed by the placebo intervention must be 
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outweighed by the value of the knowledge generated. The first standard asks us to consider whether 
the risks are necessary; the second standard asks us to consider whether the risks are proportionate 
to scientific value. Research ethics committees commonly struggle with the assessment of scientific 
value, and use of the “value-validity framework” is recommended. 33 The assessment of scientific 
value requires that (1) the research question is clinically important, (2) the hypothesis is justified by 
the current state of evidence, and (3) the study is well situated in a research portolio. 33 
Lastly, the issue of patient consent is foremost in any discussion of placebo surgical trials. Surgical 
trials with a placebo control are inherently complex studies and conveying clearly to prospective 
participants what is at stake is a challenge. There is a threat from so-called therapeutic 
misconception, whereby research participants systematically misunderstand research elements, 
such as randomization or placebos as being designed to benefit them directly 34. Full disclosure is 
therefore imperative to ensure the patient is aware that they may receive a surgical intervention 
omitting the presumptive critical surgical element. Informed consent must clearly identify which 
procedures hold the evidence-based prospect of direct benefit (where such evidence exists) and 
which are primarily performed to further science only. Inter alia, it is important that surgical 
placebos are not described in therapeutic terms, such as “treatment” or “active” procedures, when 
there is no clinical indication for the placebo procedure. However, communication to the patient is 
also required on the well-founded doubts about the efficacy of the ‘real’ procedure, most often the 
reason for conducting the trial in the first place. 
As placebo surgical trials provide a potentially nontherapeutic intervention additional protections 
may be indicated. It is important to ensure adequate patient comprehension of the likely (lack of) 
benefit from placebo allocation to reduce therapeutic misconception. 
A variety of techniques have been shown to enhance comprehension in informed consent for 
research, including enhanced consent forms (i.e. simplified forms developed by an interdisciplinary 
team involving end-users) and additional discussion time 35. There is preliminary evidence that the 
modality (verbal, written, audio-visual) and who (e.g., the treating surgeon or an independent 
researcher) presents the information may also make a difference to potential trial participants in 
placebo surgical trials 36. Formal testing of participant understanding of key elements of consent, 
especially relevant to the potential participation in a placebo arm, may serve to enhance 
comprehension and document understanding 35. 
There are many arguments around the balance of the cost and financial impact to design, conduct, 
report and disseminate the findings of a placebo surgery controlled randomized trial versus the 
continued performance of the surgery in question without high level evidence. This is an ethical 
subject in itself, however, without such a study, ineffective surgery may continue with costs and 
resource consumption, crowding out more effective treatments, and with risk to patients for little or 
no benefit. 
How have placebo surgical trials been used? 
We undertook a systematic review to update the latest published literature on surgical placebo 
rationale and methods 37. The methods are shown in Text Box 1 and more details provided in Supp 
App 1.  The review updated and extended a previously reported systematic review 3 until December 
2017. Data were extracted for trial characteristics and methodological areas of interest, including: i) 
Rationale for use of placebo interventions; ii) Patient information; iii) Intervention standardisation 
and fidelity; iv) Delivery of co-interventions and anaesthesia; v) Trials offering treatment 
interventions to patients allocated to placebo; vi) How risk is minimised because of the invasive 
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placebo. The findings of the review have been written up for publication separately but a brief 
summary of findings is given below. 
Fifty articles were added giving a new total of 96 placebo-surgical RCTs. Most were for 
gastrointestinal indications (n=40, 42%) evaluating minimally-invasive luminal endoscopic 
interventions (n=44, 46%). Over two thirds randomised fewer than 100 patients (n=65, 68%) and 
approximately a third were conducted at a single site (n=31, 32%). 
The most common reason given for using placebo interventions was to quantify placebo effects (in 
response to perceived limitations of previous non-placebo-controlled trials and known/expected 
placebo effects associated with the surgical procedure under evaluation). Information provided to 
patients was variable. A small number of trials reported minimal information about standardisation 
and fidelity of interventions. Two thirds matched anaesthesia protocols between treatment and 
placebo groups and nearly half of trials offered treatment to placebo patients on conclusion of the 
trial. 
Reporting of the placebo surgery was limited and variable. This suggests there is a need for clearer 
and more consistent reporting of rationales for placebo use, patient information provision, 
standardisation and fidelity of interventions, and the use of co-interventions. 
How should a placebo-surgical intervention be designed? 
An in-depth understanding of the presumed critical surgical element is essential for placebo trial 
design. Assessment of any potential risks to patients and strategies to ensure the placebo effectively 
mimics the treatment is also required. As part of the project, we developed a framework to optimise 
the design and delivery of placebo-surgical interventions in RCTs. The DITTO (Deconstruct, Identify, 
Take out, Think risk, Optimise) framework was developed from the systematic review of published 
literature and built on a previously published typology 38 which facilitates the deconstruction of any 
invasive intervention. Full details of the framework have been published separately 39. In brief, the 
DITTO framework suggests five stages are required in the formulation of a placebo-surgical 
intervention (Table 3).  Stage 3 of DITTO, involving identification of the critical surgical element, is 
exampled by an RCT evaluating the use of endobronchial valves in patients with chronic obstructive 
pulmonary disease. The full fidelity treatment intervention involved endobronchial valves placed 
bronchoscopically to occlude all segmental bronchi of the target lobe. Patients randomised to the 
placebo group underwent diagnostic bronchoscopy only without valve placement as this was 
deemed the critical surgical element of the procedure. 40 
Who is the placebo-surgical trial being designed to inform? 
When designing a placebo-surgical trial, it is important to identify at the outset who the trial is 
attempting to inform. This will influence the overall design of the study including decisions as to 
whether a third, no-treatment arm should also be included and which outcomes to include. 
Policymakers divide into two broad groups – those who issue guidance about how interventions 
should be used in health care, and those who commission services and pay for them (or reimburse 
patients in an insurance based model). In most health systems the people who make decisions about 
service provision strive to maximise the health returns they get for their health care investment. 
They may value information about the placebo effect of an intervention differently to clinicians 
and/or patients.  
Often guideline producers want to understand how a health gain is generated, and often feel uneasy 
when a gain is mainly generated through a non-specific placebo mechanism rather than the 
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anticipated anatomical, physiological and psychological processes that the intervention’s logic model 
may suggest. For interventions which may have a significant placebo effect a guideline producer 
would like to see robust studies which explore that effect (such as a three arm study comparing 
active intervention, placebo, and usual care – discussed below). This enables them to explore any 
placebo effect which may inform the guidelines produced, will help inform a payer's decision 
whether to reimburse a treatment, and suggest further research to explore or modify the 
intervention 41,42  
Should a placebo-surgical trial have a no intervention arm? 
There are four broad possible categories of groups (arms) in a surgical placebo trial: 1) the index 
surgical intervention being studied, 2) a placebo control (with varying levels of fidelity from 
simulated surgery/minimal skin incisions to near full fidelity); 3) non-operative care and 4) a no 
intervention group. The value of a no-intervention arm should always be considered. 
Non-operative care has the advantage of reflecting the real-life alternatives (surgery versus a 
different type of treatment). The disadvantage is that it does not allow testing of any direct or 
placebo effect of non-critical aspects of the procedure, including patient expectations and 
concomitant treatments. It provides evidence for most appropriate treatment rather than 
fundamental efficacy. 
A no intervention arm has the advantage of measuring the natural history of the condition without 
any treatment. It is useful to show how beneficial any surgery can be compared with doing nothing 
at all. A change in outcome may still be observed in a no intervention arm for various reasons (such 
as a Hawthorne effect and regression to the mean), which will also contribute to the observed effect 
in all groups. Nevertheless, the absence, or presence of only a modest, difference in the observed 
effect between surgery and no intervention would cast serious doubt on the value of the surgery 
regardless of the mechanism. Similar to a non-surgical control, the no intervention group cannot 
take account of any placebo effect due to surgery and cannot provide any information about the 
proposed mechanism for benefit. Whether or not the straightforward refutation of the mechanism 
for the effects of surgery (using a two armed comparison, placebo v normal surgery) is sufficient to 
conclude on surgical benefit overall remains a matter of debate. 
It is argued here that a placebo trial including a no treatment comparison may be scientifically 
superior but considering the resource requirement, may not always be possible or justified. Two arm 
surgical trials can also be very useful and informative. A decision on the number and type of arms 
should reflect the research question and be considered in terms of sample size and analysis, ethics 
and trial feasibility. A study with the focus on mechanism and an assumed subsequent efficacy can 
positively utilise a two arm approach. A study wanting to additionally explore the value of surgery 
overall, regardless of mechanism, is better served by a three arm study with a no treatment control. 
This is despite the potential for so called “resentful demoralisation” in patients having an 
unarticulated or hidden preference for surgery. 
Finally, in terms of trial conduct, the potential for crossover is most certainly greater in a three arm 
study with a no treatment control. The threat and implications of this must be weighed against the 
advantages stated above. A feasibility study assessing both options may be sensible before 
embarking on a definitive design. 
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IDENTIFYING AND MITIGATING RISK IN PLACEBO SURGICAL TRIALS 
The ethics literature on the use of placebo-surgical controls stresses the need for any potential risk 
from use of a placebo to be mitigated. The evidence on risk is mixed. The review by Wartolowska et 
al. showed that placebo-surg0ical controlled trials did not appear to carry any greater risk than any 
other treatment or control group. However, most of the placebo RCTs in that review only evaluated 
endoscopic or minimal access interventions. A review from the Study Center of the German Surgical 
Society also found that placebo-controlled serious adverse events were similar between true 
intervention and placebo groups and raised a concern that trials of more invasive placebo 
interventions might entail significant risks for study participants 4. This issue is highlighted by trials 
such as the ORBITA study in interventional cardiology. The placebo group were in this case found to 
have a greater number of adverse events than the normal treatment leading to difficulties and 
contention in interpretation.43 
Assessing risks of a placebo-surgical control, especially in relation to fidelity, is complex and difficult 
to quantify. Inert treatments such as low or minimum fidelity surgery may seem to have less risk 
than a surgical procedure with higher fidelity (in which more tissues may be involved), but this 
simple model may not hold. For example, those undergoing a placebo-surgical procedure, despite a 
priori higher risk, may still experience apparent benefit (although not achieved through any known 
[or theoretically causal] mechanism). Similarly, the apparent “safety” of a minimum fidelity 
procedure, in which there is little tissue damage, is tempered by the risk of anaesthetic 
complications. It should be remembered that the risk of any anaesthetic complication or surgical site 
infection after incision will apply to all groups undergoing surgery and similar anaesthesia (including 
those in the placebo arm). Discussion should include the situation when a surgical treatment's risks 
in a "low/minimal fidelity" placebo surgery group can potentially outweigh the benefits of the study 
findings to society.  This can be difficult to reconcile. It is not clear how much risk is “too much” and 
when a placebo surgery control group trial is "not worth it". It remains a complex area and will 
depend on individual procedure risk plus routine surgical risk (anaesthetic etc.) with consideration of 
the perceived capacity to benefit from the specific surgery in question. 
Previous literature has suggested various strategies for risk mitigation including: 
 Restriction of eligible patients to those with a low clinical risk profile (e.g. restriction to ASA 
grades 1&2) 
 Reducing the invasiveness of the surgical placebo (this forms part of the balance between 
fidelity and risk alluded to above) 
 Review of the form of anaesthesia used for the placebo-procedure 
 Use of only highly experienced surgeons 
 Enhanced monitoring with oversight committees 
It is important, therefore, that all means of risk mitigation are explicitly outlined before undertaking 
a placebo control surgical trial. Where the overall risk of any placebo-surgical control is deemed to 
be unacceptably high (despite all possible risk mitigation strategies) a placebo-controlled design 
should not be used.  However, without a sufficiently robust trial the surgery may continue unabated 
with all patients continuing to be subjected to all risks related to the procedure. In this situation, the 
more risky the procedure, the more urgent the need for a sufficiently robust (placebo-surgical) trial. 
TRIAL CONDUCT ISSUES FOR PLACEBO- SURGICAL TRIALS 
There are a number of key considerations which must be accounted for in the trial conduct phase.  
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Nomenclature for patients 
The nomenclature for patients in placebo-surgical trials is important and patient representatives are 
uneasy with descriptors such as “deception” and “sham” for surgical evaluation 44. Whilst such terms 
may often be seen in a scientific or trial design context, they are less acceptable to patients due to 
their negative connotations and should be avoided. 
Informed consent 
As identified earlier, as placebo-surgical trials pose an unusually high degree of nontherapeutic risk 
ensuring enhanced information for informed consent is important. It is proposed that consenting 
material would include, but not be limited to:  
 A full description of the placebo-surgical procedure; 
 A statement that whilst benefit may accrue through undergoing a placebo-surgical procedure, 
that there is no known mechanism by which the placebo surgery should result in direct benefit 
for the index complaint; 
 Recognition that the use of the placebo-surgical procedure is for research purposes; 
 The need to avoid language in the consent process that may unwittingly promote any 
therapeutic misconception; 
 Possible risks or discomforts linked to both index and the placebo-surgical procedure 
The proposed level of fidelity of the placebo control can be helpful in deciding what information 
should be communicated to potential placebo surgical trial participants. The concept helps avoid 
therapeutic misconception in trials of this type. Any information should also clearly describe the 
standard index surgical procedure for the condition should they not participate in the trial and 
outline the known benefits and risks of this standard surgery. 
Recruitment 
Maximising recruitment for a placebo control surgical trial is an important concern. A previous 
systematic review found that slow recruitment, due to difficulties finding eligible patients who agree 
to participate, was the major barrier to successful trial completion 5. The wider literature has also 
noted that individuals can hold inherent beliefs and preferences about surgery as an intervention 
per se, which may consequently affect their willingness to participate in a placebo-surgical trial 
although this can be measured and accommodated for 45. Randomisation, however, ensures that any 
such confounder (and indeed any other unknown confounder) is balanced across intervention arms. 
There are many reasons for poor recruitment to placebo surgical trials but the testing of treatments 
that are already widely accepted, available and affordable, despite an absence of high certainty 
evidence supporting their use, is often cited. In such a case, it has been postulated that both 
surgeons and patients may be reluctant to accept a 50% chance of placebo (for a two arm trial), 
particularly when placebo involves invasive surgery. This could be partially mitigated by inclusion of 
a third arm non-surgical treatment although this would increase trial complexity and cost. 
Strategies are being developed to improve recruitment for surgical placebo trials. Recruitment 
communication planning is crucial. This involves identifying and engaging all relevant stakeholders, 
identifying where people seek treatment and information, developing and testing tailored messages 
and creative materials, selecting appropriate delivery channels and messengers, and monitoring and 
evaluating process and performance. Donovan et al. 46 have developed the Quintet Recruitment 
Intervention for optimising recruitment and informed consent into trials based upon identification 
of the motivators and barriers for trial participation. Increasingly, business models and modern 
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marketing theory and techniques have also been used to inform strategies for recruitment 47-49. The 
idea is to achieve public buy-in by highlighting prestige and legitimacy, both signalling worthiness of 
the placebo design. Empirical work has shown that when well informed, patients can be willing to 
take part in placebo-surgical trials and highlight many positive reasons for doing so44  
Although it is known that the preferences of patients and health professionals, including surgeons, 
can have a decisive influence upon trial recruitment 50 many questions remain unanswered 51. These 
include whether transmission of preference can be mitigated if consent is obtained by trained and 
ideally neutral recruiters; whether well-informed patients are more or less likely to accept 
randomisation; and whether or not surgeons should be allowed to restrict randomisation to eligible 
patients only when personally uncertain as to which intervention would be the best option for an 
individual patient 50. Patient engagement is also critical to the future value and success of placebo 
controlled surgical trials. In particular, patient representatives can help with identifiable issues such 
as the ‘unblinding’ stage and how patients know both when and how they can access this 
information. 
One of the strategies observed in the recent review was to offer participants randomised to the 
placebo control group the ‘active’ intervention once the primary endpoint for that individual has been 
assessed. Whilst this approach appears ethical and is commonly used, it essentially exposes the 
patient to more risk (i.e. the risks associated with the placebo surgery and then from an unproven 
intervention). For this reason, (and unless clinician autonomy appropriately overrides trial convention) 
the offering of the definitive treatment should likely be reserved until after a final analysis. 
The issue of quality control also arises for the surgical procedure. If information on mechanism is 
required (and it mostly is from these studies) then the surgery should have a definite minimum 
quality and be performed by experienced surgeons. The “can it work" question tends to trump the 
“does it work” question and this mandates the use of highly competent surgeons. Evaluation of 
surgical quality of all surgeries performed in such studies may be needed for validation. 
Involvement and engagement of other key stakeholders 
The public needs to be better educated about surgical evidence and, despite several strong initiatives 
to improve the situation, there remains a lack of high quality evidence for surgical procedures. 
Engagement and acceptance from the public that these trials are required is essential. Previous 
research has highlighted the importance of identifying and engaging key stakeholders beyond the 
inclusion of the surgeon (e.g. patients, anaesthetists, operating theatre teams, ward nurses. health 
service managers, and policy-makers) from the outset 6. For example, anaesthetists are key clinical 
stakeholders and are crucial in decisions as to how risk can be minimised in the placebo-surgical 
intervention. The peri-operative period is where the greatest risk to patients lies in placebo trials and 
therefore the area where the greatest focus comes from clinical, ethical, regulatory and other risk 
management stakeholders. 
INTERPRETATION AND TRANSLATION INTO CHANGE OF POLICY AND PRACTICE 
In over half of the placebo controlled trials of surgery so far reported in the peer reviewed literature 
the results have shown no benefit of the definitive procedure over the placebo control 3. In many 
others the placebo effect remains strong but sits alongside a small but genuine treatment effect from 
the procedure. The presence of some effect from the index procedure is, perhaps, not surprising 
bearing in mind the ethical and academic justifications required for the use of a surgical placebo 
control. Justifications must include some reasonable preliminary evidence that part or all of the 
treatment effect of the surgical procedure under investigation might be due the placebo effect. 
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The investigators responsible for undertaking and reporting such trials must, therefore, anticipate that 
the results of the trial will be disruptive to accepted clinical care pathways and guidelines. 
Investigators should also expect, and be prepared for, push-back and resistance from clinicians and 
patients whose beliefs and convictions are being challenged by the results. Such trials will also 
generate interest from other stakeholders including payers (state and insurance based), press and the 
media. There may be an argument to call for an increase in the use of placebo controls for RCTs in 
surgery to elucidate mechanisms and eliminate redundant procedures. 
Experience with placebo controlled trials of knee arthroscopy suggest there can be a significant lag 
between evidence becoming available to a significant change in practice. In the case of knee 
arthroscopy for osteoarthritis the original publication was in 2002 yet it has taken 15 years for the 
findings to be partially adopted 24. Similar resistance from the clinical community has been 
encountered with trials of vertebroplasty for osteoporosis 52 and, more recently, subacromial 
decompression for shoulder pain 25. Consistent features of the resistance are, firstly, a belief by 
members of the surgical community that the patients recruited to the trial do not represent the usual 
population undergoing the procedure and, secondly, an assertion that the surgeons involved in the 
trial were not sufficiently expert in the procedure. In other words, the trial results “do not apply to me 
and my practice”. An illustrative example of this was the response from 15 combined Surgical 
Associations of a single country to the CSAW placebo-controlled trial for subacromial decompression 
surgery 25 which stated that “contrary to previous reports, the CSAW trial does not provide any new 
insights” and “for [this institution’s] Health System there are no consequences from the CSAW study”. 
In contrast, the National Health Service in the UK, short of de-implementing subacromial 
decompression, moved to categorise the procedure where it can only be provided if pre-conditions 
are met. 
In anticipation of these issues, it is important to plan for the implementation and impact of findings 
with full engagement of all the relevant stakeholders, from the outset including key leaders in patient 
groups, professional associations and clinical communities involved in routinely delivering the 
treatment under investigation. If the results are likely to have global implications then an international 
approach to evaluation should be adopted. Insights from implementation science are also particularly 
relevant in this regard, with a range of theory-informed and evidence-based strategies available to 
help address expected barriers to behaviour change 53. 
Once the results are known, then the implications for shared decision-making and clinical practice 
should be explored. Advice for patients should include information about the likely benefits of both 
the definitive and alternative treatments.  
KEY MESSAGES 
Our review has described how placebo controls may justifiably be used in randomised controlled trials 
of surgical interventions provided there is a strong scientific and ethical rationale for the study. A 
surgical placebo control is not appropriate for all evaluations of surgery. They may be best reserved 
for operations associated with lower surgical complication risk, potentially low efficacy, unjustified 
usage, and where a significant placebo response is expected. Against a complex set of ethical issues, 
it is particularly important that these trials have the greatest possible chance to answer the primary 
research question in a robust manner (high internal validity) with high generalizability for the relevant 
clinical community (high external validity). New surgical procedures of unknown value should also be 
evaluated and may benefit from placebo control investigation. It is important, however, that they are 
designed appropriately and that any risks associated with the placebo-surgical control procedure are 
mitigated. Considering levels of fidelity to the index surgical procedure provides a useful lens through 
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which to conceptualise the construction of a surgical placebo together with associated benefits and 
risks. A practical checklist (ASPIRE – Applying Surgical Placebo In Randomised Evaluations checklist), 
which summarises the learning points from the review and represents a minimum standard which 
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Example relevant to placebo-surgery 
Treatment 
characteristics 
A placebo-surgical control that is highly similar in its characteristics to the “real” 
procedure may influence participants’ response to the placebo procedure 
Healthcare setting 
Having a placebo-surgical procedure conducted in an operating theatre, with all the 
enhanced procedures that entails, might affect participants’ response to the placebo 
Clinician 
characteristics 
Participants’ placebo response may be influenced by the perceived high status of 
the practitioner (the surgeon) performing the placebo procedure 
Patient 
characteristics 
A patient’s previous experience of undergoing surgery and how it affected them 
might influence their response to a surgical placebo 
Patient-clinician 
interaction 
Where the surgeon has detailed and extensive interaction with the patient, this may 











Table 3: Stages of the DITTO framework 
 
DITTO Stage Description 
Stage 1 
Deconstruct the treatment intervention, including the co-interventions. The 
updated typology is used to deconstruct the treatment intervention resulting in a 
comprehensive list of treatment components and steps, including co-
interventions. 
Stage 2 
Identify the critical surgical element; The critical surgical element (which could 
be one or more components or steps) in the surgical intervention is established 
and thus which treatment components/steps are included or not in the placebo 
intervention. 
Stage 3 
Take out the critical surgical element: The critical element is omitted from the 
proposed placebo intervention. 
Stage 4 
Think risk and feasibility Once the critical surgical element has been omitted it is 
important to take account of potential risk to patients, feasibility and the role of 
the placebo intervention within the RCT (e.g. as a control intervention to 
elucidate treatment mechanism). This may result in further components or steps 
being omitted from the placebo intervention.  
Stage 5 
Optimise placebo: The use of placebo optimisation strategies are to be 

























†Cousins S, Blencowe NB, Tsang C, et al. Reporting of key methodological issues in placebo-controlled 
randomised trials of invasive procedures, including surgery, needs improvement: a systematic review. J Clin 




Systematic review methods† 
Eligibility criteria 
Articles reporting RCTs (including long-term follow ups and protocols) comparing an 
invasive procedure with a placebo procedure in living humans were included. Pilot RCTs 
retrieved by the review update search were included as a source of potentially useful 
information about methods. Interventional procedures that change the anatomy and 
requires a skin incision or the use of endoscopic techniques were included. ‘Placebo’ 
referred to a surgical placebo, a sham surgery, or a procedure intended to mimic the 
active intervention. Excluded were RCTs that assessed medicinal products or dental 
interventions, non-randomised studies, reviews, editorials, letters and conference 
abstracts. 
Searches conducted 
Articles identified in a previous review [Wartolowska 2016] published between database 
inception and 14th of November 2014 were included (n=63). Searches using the same 
search terms and electronic databases (Ovid MEDLINE, Ovid EMBASE and CENTRAL) 
were conducted to identify RCTs published from 15th November to 31st December 
2017. Additional articles, with no restriction on publication date, were identified by 
hand searching references of included articles and expert knowledge. 
Screening articles 
All articles retrieved from the current search (November 15th – December 31st 2017) 
were imported into an Endnote database (EndnoteTM, version X8.0.2). Titles and 
abstracts were screened for eligibility and full texts of potentially eligible articles were 









Rationale & ethics: 
 Justify the scientific rationale for the use of a placebo-surgical control 
 Justify how the use of placebo adheres to accepted ethical principles: 
o Is there equipoise? 
o Is it evaluating a novel surgical procedure in a condition for which there is no proven, 
effective surgical intervention or is it evaluating a procedure in common use for which the 
evidence base is poor? 




 Identify who the trial is designed to inform (and thus whether the inclusion of a no intervention arm 
is also desirable) 
 Identify the critical surgical element through adoption of the DITTO framework (using pilot and 
feasibility work as appropriate) 
 Outline the placebo-surgical control in terms of its level of fidelity to the index surgical procedure 
 Provide a clear and detailed description of the components of the placebo-surgical intervention 
 Outline how mitigation of risk of the placebo-surgical control has been considered 
 Engage key stakeholders (including patients, anaesthetists, physiotherapists and primary care 




 Avoid the use of terms such as “sham” or “fake” surgery 
 Engage participants in the production of the trial including patient information  
 Provide the following information in patient information leaflets: 
o a full description of the placebo and index surgical procedure 
o a statement that whilst benefit may accrue through undergoing a placebo-surgical 
procedure, that there is no known mechanism by which the placebo surgery should result 
in direct benefit for the indicated complaint  
o recognition that the use of the placebo-surgical procedure is being used predominantly 
for research purposes  
o information on the possible risks or discomforts linked to the index and placebo-surgical 
procedure 
 In patient information leaflets, surgical placebos should not be described in terms that may 
unwittingly lead participants to believe that the placebo-surgery brings benefit in and of itself 
 Ensure balance in the information provided on both the index surgical procedure and the placebo-
surgical procedure 
 Consider use of enhanced processes (eg decision-aids) to facilitate patient understanding of the pros 
and cons for them of participating in a placebo-surgical trial 
 Consider use of enhanced recruitment processes (eg Quintet-type approaches) to facilitate and 
optimise recruitment processes 
 Consider enhanced monitoring of the trial to allow early stopping if benefit or harms clearly observed 
early in the index surgical procedure group 
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Interpretation & Translation: 
 Prepare in advance for dissemination and implementation of findings from the trial 
 Ensure early inclusion of key leaders from patient groups, professional associations and clinical 
communities, systematic reviewers/guideline makers, policy makers involved in routinely delivering 
the treatment under investigation 
 Consider insights from implementation science for the effective translation of trial findings into 
change of practice (eg use of theory-informed, evidence-based strategies to address expected 
barriers to behaviour change) 
 Consider the implications for shared decision-making and clinical practice early - including advice for 
patients about what alternative treatments are available if the implications are that it is anticipated 
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Placebo comparisons are increasingly being considered for randomised trials assessing the efficacy 63 
of surgical interventions. The aim of this paper is to provide a summary of current knowledge on 64 
placebo controls in surgical trials. 65 
A placebo control is a complex type of comparison group and, although powerful, presents many 66 
challenges in a surgical setting. This review outlines what a placebo-surgical control entails and our 67 
understanding of the placebo phenomenon in the context of surgery. It considers when placebo-68 
surgical controls are acceptable (and when they are desirable) in terms of ethical arguments and 69 
regulatory requirements, how a placebo-surgical control should be designed, how to identify and 70 
mitigate risk for participants in placebo surgical trials, how such trials should be conducted and 71 
interpreted. 72 
Use of placebo control is justified in randomised controlled trials of surgical interventions provided 73 
there is a strong scientific and ethical rationale. Surgical placebos may be most appropriate where 74 
there is poor evidence on the efficacy of the procedure and a justified concern that results of a trial 75 
would be associated with high risk of bias, particularly due to the placebo effect. Surgical placebos 76 
are most suited to surgical procedures that improve quality of life with a large subjective 77 
component. Feasibility work is recommended to optimise RCT design and conduct. This review forms 78 
an outline for best practice and provides guidance, in the form of the ASPIRE (Applying Surgical 79 
Placebo in Randomised Evaluations) checklist, for those considering the use of a placebo-control in a 80 
surgical randomised controlled trial. 81 
INTRODUCTION & BACKGROUND 82 
Compelling evidence of efficacy and safety should underpin all routine clinical therapies, ideally 83 
based on data from randomised controlled trials (RCT), and surgical therapies are no exception. 84 
Whilst an RCT comparing surgical treatment to no surgical treatment provides evidence of overall 85 
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efficacy, it fails to account for certain biases, especially placebo. These potential biases are 86 
particularly high for surgical interventions, where placebo effects have been shown to have 87 
substantial magnitude and duration, often amplified by the particular context of surgical care 1,2. A 88 
surgical placebo control can be used to minimise bias but its use can be controversial as it poses 89 
potential risk to the patient with reduced potential benefit and presents ethical, design and trial 90 
conduct challenges. 91 
Previous reviews have been conducted of placebo-controlled surgical trials 2-4 including their use, 92 
issues of recruitment and feasibility, and impact on outcome and serious adverse events 5,6. These 93 
reviews have not, however, explicitly considered issues of trial design such as definition and content 94 
of placebo, when it is appropriate to use (or not use) a placebo control in a surgical trial, what 95 
factors should guide the choice of a placebo design and how that choice influences intervention 96 
standardisation. Some information on the ethical implications of surgical placebo trials is available 7-97 
12. 98 
This review aims to provide state of the art knowledge on all aspects of placebo controls in 99 
evaluation of surgery. The insights are primarily based on the outputs of a workshop funded by the 100 
UK’s National Institute of Health Research and Medical Research Council which brought together an 101 
international team of interdisciplinary experts with a strong track record of research in this field. The 102 
workshop included a systematic update of salient literature, in depth discussion of case studies and 103 
exposition of direct experience and best practice. The work culminated in the production of practical 104 
guidance for researchers; the ASPIRE (Applying Surgical Placebo in Randomised Evaluations) 105 
checklist. We have restricted our focus to studies of adults with capacity to consent to participate in 106 
surgical research. 107 
WHAT IS A “PLACEBO” IN THE CONTEXT OF SURGICAL TRIALS 108 
Understanding the placebo phenomenon 109 
Placebo effect knowledge is dominated by two main psychological theories, both of which apply to 110 
surgery. These are broadly labelled: 1) “conditioning”, a learning theory in which placebo effects are 111 
underpinned by associative learning with the placebo paired with an active treatment to trigger a 112 
physiological response; and 2) “response expectancy”, where the placebo effects are underpinned 113 
by the patient’s conscious or unconscious expectation that the placebo will have a particular effect 114 
13. Colloca and Miller integrated the learning and response expectancy theories to suggest that 115 
patient expectations are the central psychological mechanism that mediate placebo effects 14. 116 
According to this model, the brain decodes the psychosocial context, formulating (conscious or 117 
unconscious) expectations about outcome that then trigger placebo responses. In turn these 118 
expectations are shaped by learning mechanisms around three types of “signs” (signs are things that 119 
convey specific meanings to individuals) in the psychosocial context 15: 1) indices which generate 120 
expectations through sensory or memory-based associations for individuals; in essence a 121 
conditioned response 16; 2) symbols, which generate expectations through culturally-specific 122 
conventions including language, ritual and doctor-patient communication 17; and 3) icons which 123 
generate expectations through perceived similarities with the object, in short, expectations through 124 
social learning mechanisms 18. 125 
The manner in which patients are informed about the placebo control also shapes patients’ 126 
expectations. Any imbalance in the tone and quantity of information given about the benefits of the 127 
index procedure compared to that given for the placebo control can be stark and can influence 128 
outcome 19. 129 
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Further work has characterised how different domains of the psychosocial context of healthcare 130 
(including the setting, clinician characteristics, etc.) are at play in clinical trials and may influence the 131 
response to a surgical placebo.  These key domains include the treatment characteristics; the 132 
healthcare setting; clinician characteristics; patient characteristics; and the patient-clinician 133 
interaction. Examples of the ways that they may influence the placebo response is presented in  134 
(Table 1). 20,21  With regard to the placebo response in general, it should also be noted that there is 135 
some suggestion of genetic susceptibility to placebo with biomarkers indicating at least a moderate 136 
influence of genes on placebo response22. Furthermore, a largely unexplored aspect of placebo is the 137 
geographic and cultural differences in patients that could influence a response. Both such factors 138 
would apply to surgical placebos similarly to that of pharmaceutical placebo but would also apply 139 
equally across groups in a randomised design. 140 
Definition of a surgical placebo 141 
In this paper, surgery is defined as an invasive procedure using any access to the body (incision, 142 
natural orifice or percutaneous), includes use of instrumentation and operator skill 23. One important 143 
distinction to highlight is between the concept of placebo for evaluation purposes, as in an 144 
experimental placebo control (as described in this paper), and the notion of purposely using placebo 145 
for benefit or treatment. 146 
A clear definition of experimental placebo is lacking for surgical trials and classical definitions can 147 
introduce conceptual confusion rather than clarity. The blurred lines for surgical placebo are 148 
epitomised by the various descriptions in the literature. These vary from “a surgical intervention 149 
with theoretically little benefit”5 to “sham” surgery (entirely simulated surgery or small superficial 150 
incision only)24 to a “placebo surgical intervention”, a procedure in which presumed “active” 151 
components of the procedure or the critical surgical element have been removed 25. In the latter, the 152 
“placebo surgical intervention” consists of routine delivery of most of the operation, but with 153 
exclusion of the presumptive “active component”. However, identification of, and conceptual clarity 154 
in defining the “critical surgical element” in surgery can be far from straightforward. 155 
Rather than using the all-encompassing and generic “placebo control” to describe any form of 156 
placebo content, greater clarity can be achieved by describing the placebo control in terms of its 157 
fidelity or proximity to the complete surgical procedure 26. Varying levels of fidelity are possible from 158 
minimal no fidelity, in which there is little similarity to the complete surgical intervention (i.e. skin 159 
incisions only,  and thus resemblinge what surgeons would have traditionally described as a “sham” 160 
treatment) all the way to treatment with a complete set of surgical attributes, viz. maximum fidelity 161 
(i.e. the surgical procedure under evaluation). In between these extremes  a high fidelity placebo 162 
may have identical surgical content and attributes to the complete surgical procedure but solely 163 
without the presumed active or critical component. A low fidelity placebo may have fewer surgical 164 
components and less more closely resemble the complete surgical procedure what surgeons would 165 
have traditionally described as a “sham” treatment (Table 2). 166 
For example when evaluating the efficacy of arthroscopic subacromial decompression of the 167 
shoulder various choices for the placebo control exist. Maximum fidelity is the complete 168 
decompression surgery; a high fidelity placebo may be identical surgery but without removal of bone 169 
only; a low fidelity placebo may be very similar identical surgery but without removal of bone/ or 170 
soft tissue and lacking some other operative procedures i.e.; just the insertion of an arthroscope; 171 
and a minimum  or no fidelity treatment being surgical skin incisions only. Similarly, in a study of 172 
endoscopic radiofrequency ablation in patients with dysplastic Barrett’s esophagus the normal or 173 
maximum fidelity intervention involved ablation using a catheter. Patients randomised to the 174 
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placebo intervention group underwent a lower fidelity procedure involving upper endoscopy, 175 
esophageal intubation and measurement of esophageal inner diameter only.27 176 
It should be noted that this working framework is dependent on the theoretical premises of the 177 
operation and postulation of a “critical surgical element”.  This is not always possible, especially with 178 
surgeries that create effect by a multi-modal or dependent set of procedures. 179 
WHEN ARE PLACEBO-SURGICAL CONTROLS ACCEPTABLE?  180 
Surgical placebos may be most appropriate where there is poor evidence on the efficacy of the 181 
procedure and a justified concern that the results of an open trial would be associated with high risk 182 
of bias.Surgical placebos may be most appropriate where the benefits of surgery are not life-saving, 183 
but involve improvement in quality of life with a significant subjective component. 184 
Ethical considerations are fundamental to the decision as to whether one can use a surgical placebo 185 
control. Patients participating in a placebo controlled surgical trial are exposed to the risks of a 186 
surgical intervention that lacks the presumptive causally effective element (i.e. the critical surgical 187 
element). Participants are, therefore, potentially being exposed to some of the risks of surgery with 188 
less of the perceived benefits. Ethical standards suggest, however, that exposing research 189 
participants to such risks is allowed provided equipoise exists among the study arms, study harms 190 
have been minimised and are acceptable to the participant 28,29. 191 
The use of a placebo control in a surgical RCT is consistent with the ethical principle of beneficence 192 
provided the benefits and harmsrisks posed are reasonable and risks are offset by the social value of 193 
the study 7. One way to determine whether the benefits and harms of a trial are acceptable is to 194 
perform component analysis 30. In component analysis, a trial’s therapeutic procedures must be 195 
considered separately from its nontherapeutic procedures. However, in surgical placebos this 196 
separation is not straightforward as a placebo intervention lacking the critical surgical element may 197 
nonetheless induce physiological changes in the patient. Thus, we distinguish between the placebo 198 
control that includes warranted therapeutic procedures, in which the prospect of direct patient 199 
benefit is supported by evidence, and nontherapeutic procedures, in which no such warrant exists 200 
and the procedure is conducted for scientific purposes. 201 
The analysis of benefits and harms in placebo controlled surgical trials is further complicated by the 202 
fact that the placebo control includes both warranted therapeutic and nontherapeutic procedures. 203 
To address this, a two-step ethical analysis is required. First, one must consider whether the use of 204 
any placebo control is justified i.e. whether clinical equipoise holds in the face of a placebo control. 205 
Clinical eEquipoise is defined as “a state of disagreement or uncertainty in the informed, expert 206 
medical community about the relative clinical merits of the intervention arms in a trial” 31. 207 
Disagreement or uncertainty should be understood in terms of the state of evidence rather than 208 
unsubstantiated opinion. If equipoise exists, then it does not matter to the surgeon which trial arm 209 
the participant is placed into; given the state of knowledge at the beginning of the trial, both arms 210 
are deemed to be broadly consistent with competent surgical medical care 30. A placebo control is 211 
permissible to evaluate a novel surgical procedure in a condition for which there is no proven, 212 
effective surgical intervention. Additionally, the case for placebo control design for surgery becomes 213 
stronger when the evidence base supporting a procedure in common use is poor, such as for 214 
vertebroplasty 32. Although the surgical procedure is commonly used, equipoise exists because of the 215 
lack of supporting evidence.32 Thus, in In both cases, the use of a placebo control is consistent with  216 
clinical equipoise because there is sufficient uncertainty over whether surgery offers any advantage 217 
over medical non surgical management alone. 218 
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If placebo is justified, then the appropriate level of fidelity to the surgical intervention must then be 219 
considered. To make this determination, two standards are relevant 30. First, the harms posed by the 220 
intervention must be minimized. Second, the risks posed by the placebo intervention must be 221 
outweighed by the value of the knowledge generated. The first standard asks us to consider whether 222 
the risks are necessary; the second standard asks us to consider whether the risks are proportionate 223 
to scientific value. Research ethics committees commonly struggle with the assessment of scientific 224 
value, and use of the “value-validity framework” is recommended. 33 The assessment of scientific 225 
value requires that (1) the research question is clinically important, (2) the hypothesis is justified by 226 
the current state of evidence, and (3) the study is well situated in a research portolio. 33. 227 
Lastly, the issue of patient consent is foremost in any discussion of placebo surgical trials. Surgical 228 
trials with a placebo control are inherently complex studies and conveying clearly to prospective 229 
participants what is at stake is a challenge. There is a threat from so-called therapeutic 230 
misconception, whereby research participants systematically misunderstand research elements, 231 
such as randomization or placebos as being designed to benefit them directly 34. Full disclosure is 232 
therefore imperative to ensure the patient is aware that they may receive a surgical intervention 233 
omitting the presumptive critical surgical element. Informed consent must clearly identify which 234 
procedures hold the evidence-based prospect of direct benefit (where such evidence exists) and 235 
which are primarily performed to further science only. Inter alia, it is important that surgical 236 
placebos are not described in therapeutic terms, such as “treatment” or “active” procedures, when 237 
there is no clinical indication for the placebo procedure. However, communication to the patient is 238 
also required on the well-founded doubts about the efficacy of the ‘real’ procedure, most often the 239 
reason for conducting the trial in the first place. 240 
As  some placebo surgical trials provide ose an unusually high degree of a potentially nontherapeutic 241 
interventionrisk, additional protections may be indicated. It is important to ensure adequate patient 242 
comprehension of the likely (lack of) benefit from placebo allocation to reduce therapeutic 243 
misconception. 244 
A variety of techniques have been shown to enhance comprehension in informed consent for 245 
research, including enhanced consent forms (i.e. simplified forms developed by an interdisciplinary 246 
team involving end-users) and additional discussion time 35. There is preliminary evidence that the 247 
modality medium (verbal, written, audio-visual) and who (e.g., the treating surgeon or an 248 
independent researcher) presents the information may also make a difference to potential trial 249 
participants in placebo surgical trials 36. Formal testing of participant understanding of key elements 250 
of consent, especially relevant to the potential participation in a placebo arm, may serve to enhance 251 
comprehension and document understanding 35. 252 
There are many arguments around the balance of the cost and financial impact to design, conduct, 253 
report and disseminate the findings of a placebo surgery controlled randomized trial versus the 254 
continued performance of the surgery in question without high level evidence. This is an ethical 255 
subject in itself, however, without such a study, ineffective surgery may continue with costs and 256 
resource consumption, crowding out more effective treatments, and with risk to patients for little or 257 
no benefit. 258 
 259 
How have placebo surgical trials been used? 260 
We undertook a systematic review to update the latest published literature on surgical placebo 261 
rationale and methods 37. The methods are shown in Text Box 1 and more details provided in Supp 262 
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App 1.  The review updated and extended a previously reported systematic review 3 until December 263 
2017. Data were extracted for trial characteristics and methodological areas of interest, including: i) 264 
Rationale for use of placebo interventions; ii) Patient information; iii) Intervention standardisation 265 
and fidelity; iv) Delivery of co-interventions and anaesthesia; v) Trials offering treatment 266 
interventions to patients allocated to placebo; vi) How risk is minimised because of the invasive 267 
placebo. The findings of the review have been written up for publication separately but a brief 268 
summary of findings is given below. 269 
Fifty articles were added giving a new total of 96 placebo-surgical RCTs. Most were for 270 
gastrointestinal indications (n=40, 42%) evaluating minimally-invasive luminal endoscopic 271 
interventions (n=44, 46%). Over two thirds randomised fewer than 100 patients (n=65, 68%) and 272 
approximately a third were conducted at a single site (n=31, 32%). 273 
The most common reason given for using placebo interventions was to quantify placebo effects (in 274 
response to perceived limitations of previous non-placebo-controlled trials and known/expected 275 
placebo effects associated with the surgical procedure under evaluation). Information provided to 276 
patients was variable. A small number of trials reported minimal information about standardisation 277 
and fidelity of interventions. Two thirds matched anaesthesia protocols between treatment and 278 
placebo groups and nearly half of trials offered treatment to placebo patients on conclusion of the 279 
trial. 280 
Reporting of the placebo surgery was limited and variable. This suggests there is a need for clearer 281 
and more consistent reporting of rationales for placebo use, patient information provision, 282 
standardisation and fidelity of interventions, and the use of co-interventions. 283 
How should a placebo-surgical intervention be designed? 284 
An in-depth understanding of the presumed critical surgical element is essential for placebo trial 285 
design. Assessment of any potential risks to patients and strategies to ensure the placebo effectively 286 
mimics the treatment is also required. As part of the project, we developed a framework to optimise 287 
the design and delivery of placebo-surgical interventions in RCTs. The DITTO (Deconstruct, Identify, 288 
Take out, Think risk, Optimise) framework was developed from the systematic review of published 289 
literature and built on a previously published typology 38 which facilitates the deconstruction of any 290 
invasive intervention. Full details of the framework have been published separately 39. In brief, the 291 
DITTO framework suggests five stages are required in the formulation of a placebo-surgical 292 
intervention (Table 3).  Stage 3 of DITTO, involving identification of the critical surgical element, is 293 
exampled by an RCT evaluating the use of endobronchial valves in patients with chronic obstructive 294 
pulmonary disease. The full fidelity treatment intervention involved endobronchial valves placed 295 
bronchoscopically to occlude all segmental bronchi of the target lobe. Patients randomised to the 296 
placebo group underwent diagnostic bronchoscopy only without valve placement as this was 297 
deemed the critical surgical element of the procedure. 40 298 
 299 
Who is the placebo-surgical trial being designed to inform? 300 
When designing a placebo-surgical trial, it is important to identify at the outset who the trial is 301 
attempting to inform. This will influence the overall design of the study including decisions as to 302 
whether a third, no-treatment arm should also be included and which outcomes to include. 303 
Policymakers divide into two broad groups – those who issue guidance about how interventions 304 
should be used in health care, and those who commission services and pay for them (or reimburse 305 
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patients in an insurance based model). In most health systems the people who make decisions about 306 
service provision strive to maximise the health returns they get for their health care investment. 307 
They may value information about the placebo effect of an intervention differently to clinicians 308 
and/or patients.  309 
Producers of guidelines tend to Often guideline producers want to understand how a health gain is 310 
generated, and often feel uneasy when a gain is mainly generated through a non-specific placebo 311 
mechanism rather than the anticipated anatomical, physiological and psychological processes that 312 
the intervention’s logic model may suggest. For interventions which may have a significant placebo 313 
effect a guideline producer would like to see robust studies which explore that effect (such as a 314 
three arm study comparing active intervention, placebo, and usual care – discussed below). This 315 
enables them to partition out any placebo effect which will inform the guidelines produced.  316 
For interventions which may have a significant placebo effect a guideline producer would like to see 317 
robust studies which explore that effect (such as a three arm study comparing active intervention, 318 
placebo, and usual care – discussed below). This enables them to explore any placebo effect which 319 
may inform the guidelines produced, will help inform a payer's decision whether to reimburse a 320 
treatment, and suggest further research to explore or modify the intervention 41,42   321 
Should a placebo-surgical trial have a no intervention arm? 322 
There are four broad possible categories of groups (arms) in a surgical placebo trial: 1) the index 323 
surgical intervention being studied, 2) a placebo control (with varying levels of fidelity from 324 
simulated surgery/minimal skin incisions to near full fidelity); 3) non-operative care and 4) a no 325 
intervention group. The value of a no-intervention arm should always be considered. 326 
Best Nnon-operative care has the advantage of reflecting the real-life alternatives (surgery versus a 327 
different type of treatmentbest non-operative care). The disadvantage is that it does not allow 328 
testing of any direct or placebo effect of non-critical aspects of the procedure, including patient 329 
expectations and concomitant treatments.  It provides evidence for most appropriate best 330 
treatment rather than fundamental efficacy. 331 
A no intervention arm has the advantage of measuring the natural history of the condition without 332 
any treatment. It is useful to show how beneficial any surgery can be compared with doing nothing 333 
at all. A change in outcome may still be observed in a no intervention arm for various reasons (such 334 
as a Hawthorne effect and regression to the mean), which will also contribute to the observed effect 335 
in all groups. Nevertheless, the Absence absence, or presence of only a modest, difference in the 336 
observed effect between surgery and no intervention would cast serious doubt on the value of the 337 
surgery regardless of the mechanism. Similar to a non-surgical control, the no intervention group 338 
cannot take account of any placebo effect due to surgery and cannot provide any information about 339 
the proposed mechanism for benefit. Whether or not the straightforward refutation of the 340 
mechanism for the effects of surgery (using a two armed comparison, placebo v normal surgery) is 341 
sufficient to conclude on surgical benefit overall remains a matter of debate. 342 
It is argued here that a placebo trial including a no treatment comparison may be scientifically 343 
superior but considering the resource requirement, may not always be possible or justified. Two arm 344 
surgical trials can also be very useful and informative. A decision on Justification for the number and 345 
type of arms should reflect the research question and be considered in terms of sample size and 346 
analysis, ethics and trial feasibility. A study with the focus on mechanism and an assumed 347 
subsequent efficacy can positively utilise a two arm approach. A study wanting to additionally 348 
explore the value of surgery overall, regardless of mechanism, is better served by a three arm study 349 
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with a no treatment control. This is despite the potential for so called “resentful demoralisation” in 350 
patients having an unarticulated or hidden preference for surgery. 351 
Finally, in terms of trial conduct, the potential for crossover is most certainly greater in a three arm 352 
study with a no treatment control. The threat and implications of this must be weighed against the 353 
advantages stated above. A feasibility study assessing both options may be sensible before 354 
embarking on a definitive design. 355 
IDENTIFYING AND MITIGATING RISK IN PLACEBO SURGICAL TRIALS 356 
The ethics literature on the use of placebo-surgical controls stresses the need for any potential risk 357 
from use of a placebo to be mitigated. The evidence on risk is mixed. The review by Wartolowska et 358 
al. showed that placebo-surg0ical controlled trials did not appear to carry any greater risk than any 359 
other treatment or control group. However, most of the placebo RCTs in that review only evaluated 360 
endoscopic or minimal access interventions. A review from the Study Center of the German Surgical 361 
Society also found that placebo-controlled serious adverse events  were similar between true 362 
intervention and placebo groups and raised a concern that trials of more invasive placebo 363 
interventions might entail significant risks for study participants 4. This issue is highlighted by trials 364 
such as the ORBITA study in interventional cardiology. The placebo group were in this case found to 365 
have a greater number of adverse events than the normal treatment leading to difficulties and 366 
contention in interpretation.43 367 
Assessing risks of a placebo-surgical control, especially in relation to fidelity, is complex and difficult 368 
to quantify. Inert treatments such as low or minimum fidelity surgery may seem to have less risk 369 
than a surgical procedure with higher fidelity (in which more tissues may be involved), but this 370 
simple model may not hold. For example, those undergoing a placebo-surgical procedure, despite a 371 
priori higher risk, may still experience apparent benefit (although not achieved through any known 372 
[or theoretically causal] mechanism). Similarly, the apparent “safety” of a minimum fidelity 373 
procedure, in which there is little tissue damage, is tempered by the risk of anaesthetic 374 
complications. It should be remembered that the risk of any anaesthetic complication or surgical site 375 
infection after incision will apply to all groups undergoing surgery and similar anaesthesia (including 376 
those in the placebo arm). Discussion should include the situation when a surgical treatment's risks 377 
in a "low/minimal fidelity" placebo surgery group can potentially outweigh the benefits of the study 378 
findings to society.  This can be difficult to reconcile. It is not clear how much risk is “too much” and 379 
when a placebo surgery control group trial is "not worth it". It remains a complex area and will 380 
depend on individual procedure risk plus routine surgical risk (anaesthetic etc.) with consideration of 381 
the perceived capacity to benefit from the specific surgery in question.Low fidelity interventions also 382 
have a greater risk of unblinding. 383 
Previous literature has suggested various strategies for risk mitigation including: 384 
 Restriction of eligible patients to those with a low clinical risk profile (e.g. restriction to ASA 385 
grades 1&2) 386 
 Reducing the invasiveness of the surgical placebo (this forms part of the balance between 387 
fidelity and risk alluded to above) 388 
 Review of the form of anaesthesia used for the placebo-procedure 389 
 Use of only highly experienced surgeons 390 
 Enhanced monitoring with oversight committees 391 
It is important, therefore, that all means of risk mitigation are explicitly outlined before undertaking 392 
a placebo control surgical trial. Where the overall risk of any placebo-surgical control is deemed to 393 
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be unacceptably high (despite all possible risk mitigation strategies) a placebo-controlled design 394 
should not be used.  However, without a sufficiently robust trial the surgery may continue unabated 395 
with all patients continuing to be subjected to all risks related to the procedure. In this situation, the 396 
more risky the procedure, the more urgent the need for a sufficiently robust (placebo-surgical) trial. 397 
TRIAL CONDUCT ISSUES FOR PLACEBO- SURGICAL TRIALS 398 
There are a number of key considerations which must be accounted for in the trial conduct phase.  399 
Nomenclature for patients 400 
The nomenclature for patients in placebo-surgical trials is important and patient representatives are 401 
uneasy with descriptors such as “deception” and “sham” for surgical evaluation 44. Whilst such terms 402 
may often be seen in a scientific or trial design context, they are less acceptable to patients due to 403 
their negative connotations and should be avoided. 404 
Informed consent 405 
As identified earlier, as placebo-surgical trials pose an unusually high degree of nontherapeutic risk 406 
ensuring enhanced information for informed consent is important. It is proposed that consenting 407 
material would include, but not be limited to:  408 
 A full description of the placebo-surgical procedure; 409 
 A statement that whilst benefit may accrue through undergoing a placebo-surgical procedure, 410 
that there is no known mechanism by which the placebo surgery should result in direct benefit 411 
for the index complaint; 412 
 Recognition that the use of the placebo-surgical procedure is for research purposes; 413 
 The need to avoid language in the consent process that may unwittingly promote any 414 
therapeutic misconception; 415 
 Possible risks or discomforts linked to both index and the placebo-surgical procedure 416 
The proposed level of fidelity of the placebo control can be helpful in deciding what information 417 
should be communicated to potential placebo surgical trial participants. The concept helps avoid 418 
therapeutic misconception in trials of this type. Any information should also clearly describe the 419 
standard index surgical procedure for the condition should they not participate in the trial and 420 
outline the known benefits and risks of this standard surgery. 421 
Recruitment 422 
Maximising recruitment for a placebo control surgical trial is an important concern. A previous 423 
systematic review found that slow recruitment, due to difficulties finding eligible patients who agree 424 
to participate, was the major barrier to successful trial completion 5.  The wider literature has also 425 
noted that individuals can hold inherent beliefs and preferences about surgery as an intervention 426 
per se, which may consequently affect their willingness to participate in a placebo-surgical trial 427 
although this can be measured and accommodated for 45. Randomisation, however, ensures that any 428 
such confounder (and indeed any other unknown confounder) is balanced across intervention arms. 429 
There are many reasons for poor recruitment to placebo surgical trials but the testing of treatments  430 
that are already widely accepted, available and affordable, despite an absence of high certainty 431 
evidence supporting their use, is often cited. In such a case, it has been postulated that both 432 
surgeons and patients may be reluctant to accept a 50% chance of placebo (for a two arm trial), 433 
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particularly when placebo involves invasive surgery. This could be partially mitigated by inclusion of 434 
a third arm non-surgical treatment although this would increase trial complexity and cost.  435 
 436 
Strategies are being developed to improve recruitment for surgical placebo trials. Recruitment 437 
communication planning is crucial. This involves identifying and engaging all relevant stakeholders, 438 
identifying where people seek treatment and information, developing and testing tailored messages 439 
and creative materials, selecting appropriate delivery channels and messengers, and monitoring and 440 
evaluating process and performance. Donovan et al. 46 have developed the Quintet Recruitment 441 
Intervention for optimising recruitment and informed consent into trials based upon identification 442 
of the motivators and barriers for trial participation. Increasingly, business models and modern 443 
marketing theory and techniques have also been used to inform strategies for recruitment 47-49. The 444 
idea is to achieve public buy-in by highlighting prestige and legitimacy, both signalling worthiness of 445 
the placebo design.  . Empirical work has shown that when well informed, patients can be willing to 446 
take part in placebo-surgical trials and highlight many positive reasons for doing so44 Empirical work 447 
has shown, that when well informed, patients can be willing to take part in placebo-surgical trials 448 
and highlight many positive reasons for doing so 449 
Although it is known that the preferences of patients and health professionals, including surgeons, 450 
can have a decisive influence upon trial recruitment 50 many questions remain unanswered 51. These 451 
include whether transmission of preference can be mitigated if consent is obtained by trained and 452 
ideally neutral recruiters; whether well-informed patients are more or less likely to accept 453 
randomisation; and whether or not surgeons should be allowed to restrict randomisation to eligible 454 
patients only when personally uncertain as to which intervention would be the best option for an 455 
individual patient 50. Patient engagement is also critical to the future value and success of placebo 456 
controlled surgical trials. In particular, patient representatives can help with identifiable issues such 457 
as the ‘unblinding’ stage and how patients know both when and how they can access this 458 
information.   459 
One of the strategies observed in the recent review was to offer participants randomised to the 460 
placebo control group the ‘active’ intervention once the primary endpoint for that individual has been 461 
assessed. Whilst this approach appears ethical and is commonly used, it essentially exposes the 462 
patient to more risk (i.e. the risks associated with the placebo surgery and then from an unproven 463 
intervention). For this reason, (and unless clinician autonomy appropriately overrides trial convention) 464 
the offering of the definitive treatment should likely be reserved until after a final analysis. 465 
The issue of quality control also arises for the surgical procedure. If information on mechanism is 466 
required (and it mostly is from these studies) then the surgery should have a definite minimum 467 
quality and be performed by experienced surgeons. The “can it work" question tends to trump the 468 
“does it work” question and this mandates the use of highly competent surgeons. Evaluation of 469 
surgical quality of all surgeries performed in such studies may be needed for validation. 470 
Involvement and engagement of other key stakeholders 471 
The public needs to be better educated about surgical evidence and, despite several strong initiatives 472 
to improve the situation, there remains a lack of high quality evidence for surgical procedures. 473 
Engagement and acceptance from the public that these trials are required is essential. Previous 474 
research has highlighted the importance of identifying and engaging key stakeholders beyond the 475 
inclusion of the surgeon (e.g. patients, anaesthetists, operating theatre teams, ward nurses. health 476 
service managers, and policy-makers) from the outset 6. For example, anaesthetists are key clinical 477 
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stakeholders and are crucial in decisions as to how risk can be minimised in the placebo-surgical 478 
intervention. The peri-operative period is where the greatest risk to patients lies in placebo trials and 479 
therefore the area where the greatest focus comes from clinical, ethical, regulatory and other risk 480 
management stakeholders. 481 
INTERPRETATION AND TRANSLATION INTO CHANGE OF POLICY AND PRACTICE 482 
In over half of the placebo controlled trials of surgery so far reported in the peer reviewed literature 483 
the results have shown no benefit of the definitive procedure over the placebo control 3. In many 484 
others the placebo effect remains strong but sits alongside a small but genuine treatment effect from 485 
the procedure. The presence of some effect from the index procedure is, perhaps, not surprising 486 
bearing in mind the ethical and academic justifications required for the use of a surgical placebo 487 
control. Justifications must include some reasonable preliminary evidence that part or all of the 488 
treatment effect of the surgical procedure under investigation might be due the placebo effect. 489 
The investigators responsible for undertaking and reporting such trials must, therefore, anticipate that 490 
the results of the trial will be disruptive to accepted clinical care pathways and guidelines. 491 
Investigators should also expect, and be prepared for, push-back and resistance from clinicians and 492 
patients whose beliefs and convictions are being challenged by the results. Such trials will also 493 
generate interest from other stakeholders including payers (state and insurance based), press and the 494 
media. There may be an argument to call for an increase in the use of placebo controls for RCTs in 495 
surgery to elucidate mechanisms and eliminate redundant procedures. 496 
Experience with placebo controlled trials of knee arthroscopy suggest there can be has revealed a 497 
significantlong lag between evidence becoming available to a significant change in practice. In the case 498 
of knee arthroscopy for osteoarthritis the original publication was in 2002 yet it has taken 15 years for 499 
the findings to be partially adopted 24. Similar resistance from the clinical community has been 500 
encountered with trials of vertebroplasty for osteoporosis 52 and, more recently, subacromial 501 
decompression for shoulder pain 25. Consistent features of the resistance are, firstly, a belief by 502 
members of the surgical community that the patients recruited to the trial do not represent the usual 503 
population undergoing the procedure and, secondly, an assertion that the surgeons involved in the 504 
trial were not sufficiently expert in the procedure. In other words, the trial results “do not apply to me 505 
and my practice”. An illustrative example of this was the response from 15 combined Surgical 506 
Associations of a single country to the CSAW placebo-controlled trial for subacromial decompression 507 
surgery 25 which stated that “contrary to previous reports, the CSAW trial does not provide any new 508 
insights” and “for [this institution’s] Health System there are no consequences from the CSAW study”. 509 
In contrast, the National Health Service in the UKanother country, short of de-implementing 510 
subacromial decompression, moved to categorise the procedure where it can only be provided if pre-511 
conditions are met. 512 
In anticipation of these issues, it is important to plan for the implementation and impact of findings 513 
with full engagement of all the relevant stakeholders, from the outset including key leaders in patient 514 
groups, professional associations and clinical communities involved in routinely delivering the 515 
treatment under investigation. If the results are likely to have global implications then an international 516 
approach to evaluation should be adopted. Insights from implementation science are also particularly 517 
relevant in this regard, with a range of theory-informed and evidence-based strategies available to 518 
help address expected barriers to behaviour change 53. 519 
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Once the results are known, then the implications for shared decision-making and clinical practice 520 
should be explored. Advice for patients should include information about the likely benefits of both 521 
the definitive and alternative treatments.  522 
KEY MESSAGES 523 
Our review has described how placebo controls may justifiably be used in randomised controlled trials 524 
of surgical interventions provided there is a strong scientific and ethical rationale for the study. A 525 
surgical placebo control is not appropriate for all evaluations of surgery. They may be best reserved 526 
for operations associated with lower surgical complication risk, potentially low efficacy, unjustified 527 
usage, and where a significant placebo response is expected. Against a complex set of ethical issues, 528 
it is particularly important that these trials have the greatest possible chance to answer the primary 529 
research question in a robust manner (high internal validity) with high generalizability for the relevant 530 
clinical community (high external validity). New surgical procedures of unknown value should also be 531 
evaluated and may benefit from placebo control investigation. It is important, however, that they are 532 
designed appropriately and that any risks associated with the placebo-surgical control procedure are 533 
mitigated. Considering levels of fidelity to the index surgical procedure provides a useful lens through 534 
which to conceptualise the construction of a surgical placebo together with associated benefits and 535 
risks. A practical checklist (ASPIRE – Applying Surgical Placebo In Randomised Evaluations checklist), 536 
which summarises the learning points from the review and represents a minimum standard which 537 
researchers should attain and demonstrate when designing a placebo-surgical trial, is presented in 538 
Figure 1. 539 
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Example relevant to placebo-surgery 
Treatment 
characteristics 
A placebo-surgical control that is highly similar in its characteristics to the “real” 
procedure may influence participants’ response to the placebo procedure 
Healthcare setting 
Having a placebo-surgical procedure conducted in an operating theatre, with all the 
enhanced procedures that entails, might affect participants’ response to the placebo 
Clinician 
characteristics 
Participants’ placebo response may be influenced by the perceived high status of 
the practitioner (the surgeon) performing the placebo procedure 
Patient 
characteristics 
A patient’s previous experience of undergoing surgery and how it affected them 
might influence their response to a surgical placebo 
Patient-clinician 
interaction 
Where the surgeon has detailed and extensive interaction with the patient, this may 
influence their level of response to the surgical placebo 
 809 
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Table 2: Levels of fidelity to the complete surgical intervention for placebo surgical trial design. 811 
Level of fidelity to surgical 
Intervention 
Descriptor 
Maximum Fidelity: the index 
procedure - NOT placebo 
The complete surgical intervention as specified for evaluation in an 
RCT. This is the true intervention arm of the trial. 
Placebo with High Fidelity  High fidelity with the specification of the treatment intervention (near 
complete attributes of the procedure under investigation) 
Placebo with Low Fidelity Low fidelity with the specification of the treatment intervention 
(lesser attributes of the procedure under investigation) 
Minimum Fidelity or Placebo 
with No Fidelity 
Lowest or zero fidelity with the specification of the treatment 
intervention (i.e. sham). (No attributes of the procedure under 
investigation, e.g. skin incisions only) 
 812 
 813 
  814 
Commented [DB29]: R9 (revised table) 
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Table 3: Stages of the DITTO framework 815 
 816 
DITTO Stage Description 
Stage 1 
Deconstruct the treatment intervention, including the co-interventions. The 
updated typology is used to deconstruct the treatment intervention resulting in a 
comprehensive list of treatment components and steps, including co-
interventions. 
Stage 2 
Identify the critical surgical element; The critical surgical element (which could 
be one or more components or steps) in the surgical intervention is established 
and thus which treatment components/steps are included or not in the placebo 
intervention. 
Stage 3 
Take out the critical surgical element: The critical element is omitted from the 
proposed placebo intervention. 
Stage 4 
Think risk and feasibility Once the critical surgical element has been omitted it is 
important to take account of potential risk to patients, feasibility and the role of 
the placebo intervention within the RCT (e.g. as a control intervention to 
elucidate treatment mechanism). This may result in further components or steps 
being omitted from the placebo intervention.  
Stage 5 
Optimise placebo: The use of placebo optimisation strategies are to be 
considered throughout the design process (e.g. sensory masking). 
 817 
  818 
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†Cousins S, Blencowe NB, Tsang C, et al. Reporting of key methodological issues in placebo-controlled 839 
randomised trials of invasive procedures, including surgery, needs improvement: a systematic review. J Clin 840 
Epidemiol. 2020 [Revisions submitted] 841 
 842 
 843 
  844 
Systematic review methods† 
Eligibility criteria 
Articles reporting RCTs (including long-term follow ups and protocols) comparing an 
invasive procedure with a placebo procedure in living humans were included. Pilot RCTs 
retrieved by the review update search were included as a source of potentially useful 
information about methods. Interventional procedures that change the anatomy and 
requires a skin incision or the use of endoscopic techniques were included. ‘Placebo’ 
referred to a surgical placebo, a sham surgery, or a procedure intended to mimic the 
active intervention. Excluded were RCTs that assessed medicinal products or dental 
interventions, non-randomised studies, reviews, editorials, letters and conference 
abstracts. 
Searches conducted 
Articles identified in a previous review [Wartolowska 2016] published between database 
inception and 14th of November 2014 were included (n=63). Searches using the same 
search terms and electronic databases (Ovid MEDLINE, Ovid EMBASE and CENTRAL) 
were conducted to identify RCTs published from 15th November to 31st December 
2017. Additional articles, with no restriction on publication date, were identified by 
hand searching references of included articles and expert knowledge. 
Screening articles 
All articles retrieved from the current search (November 15th – December 31st 2017) 
were imported into an Endnote database (EndnoteTM, version X8.0.2). Titles and 
abstracts were screened for eligibility and full texts of potentially eligible articles were 
retrieved to confirm eligibility. Screening was conducted independently by two 
reviewers.  
Commented [DB30]: R19 
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Rationale & ethics: 
 Justify the scientific rationale for the use of a placebo-surgical control 
 Justify how the use of placebo adheres to accepted ethical principles: 
o Is there equipoise? 
o Is it evaluating a novel surgical procedure in a condition for which there is no proven, 
effective surgical intervention or is it evaluating a procedure in common use for which the 
evidence base is poor? 




 Identify who the trial is designed to inform (and thus whether the inclusion of a no intervention arm 
is also desirable) 
 Identify the critical surgical element through adoption of the DITTO framework (using pilot and 
feasibility work as appropriate) 
 Outline the placebo-surgical control in terms of its level of fidelity to the index surgical procedure 
 Provide a clear and detailed description of the components of the placebo-surgical intervention 
 Outline how mitigation of risk of the placebo-surgical control has been considered 
 Engage key stakeholders (including patients, anaesthetists, physiotherapists and primary care 




 Avoid the use of terms such as “sham” or “fake” surgery 
 Engage participants in the production of the trial including patient information  
 Provide the following information in patient information leaflets: 
o a full description of the placebo and index surgical procedure 
o a statement that whilst benefit may accrue through undergoing a placebo-surgical 
procedure, that there is no known mechanism by which the placebo surgery should result 
in direct benefit for the indicated complaint  
o recognition that the use of the placebo-surgical procedure is being used predominantly 
for research purposes  
o information on the possible risks or discomforts linked to the index and placebo-surgical 
procedure 
 In patient information leaflets, surgical placebos should not be described in terms that may 
unwittingly lead participants to believe that the placebo-surgery brings benefit in and of itself 
 Ensure balance in the information provided on both the index surgical procedure and the placebo-
surgical procedure 
 Consider use of enhanced processes (eg decision-aids) to facilitate patient understanding of the pros 
and cons for them of participating in a placebo-surgical trial 
 Consider use of enhanced recruitment processes (eg Quintet-type approaches) to facilitate and 
optimise recruitment processes 
 Consider enhanced monitoring of the trial to allow early stopping if benefit or harms clearly observed 
early in the index surgical procedure group 
24 
 




Interpretation & Translation: 
 Prepare in advance for dissemination and implementation of findings from the trial 
 Ensure early inclusion of key leaders from patient groups, professional associations and clinical 
communities, systematic reviewers/guideline makers, policy makers involved in routinely delivering 
the treatment under investigation 
 Consider insights from implementation science for the effective translation of trial findings into 
change of practice (eg use of theory-informed, evidence-based strategies to address expected 
barriers to behaviour change) 
 Consider the implications for shared decision-making and clinical practice early - including advice for 
patients about what alternative treatments are available if the implications are that it is anticipated 
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manuscript. 
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the reviewers' points the text 
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controlled trial). 
Done 
8. Please limit the summary to 
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n/a 
12. Please report all outcomes 
specified in the protocol. 
n/a 
13. If any exploratory outcomes 
are reported that were not pre-
specified, please make it clear 
that these analyses were post-
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t/)  for proteins and HUGO 
(http://www.genenames.org) 
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sharing statement, to be 
included at the end of the 
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plan changes after registration, 
this should be reflected in the 
statement submitted and 
published, and updated in the 
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are encouraged but not 
required. Mendeley Data 
(https://data.mendeley.com) is a 
secure online repository for 
research data, permitting 
archiving of any file type and 
assigning a permanent and 
unique digital object identifier 
(DOI) so that the files can be 
easily referenced. If authors 
wish to share their supporting 
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alternative arrangements, a 
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to in the data sharing statement. 
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REVIEWER COMMENT RESPONSE 
REVIEWER #1  
Reviewer #1: I read 
"Considerations and Methods 
for Placebo Controls in Surgical 
Trials: State of the Art Review 
and ASPIRE Guidance" by Beard 
and co-authors with interest. 
The authors have submitted a 
well written narrative review of 
the use of placebo surgery 
control groups in randomized 
trials. English language was 
used, easy to follow, with 
manuscript form and structure 
appropriate, three tables and 
one figure (none of which need 
color, can be black & white). 
References were mostly up to 
date, with 1/3 of references 
Thank you for your accurate summary of the paper and some 
excellent suggestions. 
published within past five years. 
The narrative review was a 
general overview of placebo 
surgery controls, with sufficient 
detail to grasp the impetus for 
study, and the reason for 
publication in The Lancet. There 
were no fatal flaws that should 
immediately preclude 
publication. However, there are 
major omissions listed below 
that should be added to ensure 
that this manuscript does truly 
cover all aspects of optimal 
quality placebo surgery 
controlled randomized trials in 
surgery. The authors added a 
novel checklist, ASPIRE, that can 
aid investigators in creation, 
conduct, design, interpretation, 
reporting, and dissemination of 
the study's findings. If the 
authors can make the requested 
revisions, then I would be happy 
to provide a re-review at any 
time. I thank the authors for 
their efforts, as I can only 
imagine the challenges 
associated with that many 
authors of the world's leaders 
on placebo surgery RCTs all 
writing a single manuscript and 
simply, concisely, and cohesively 
summarizing the topic - 
"complexity is your enemy. Any 
fool can make something 
complicated. It is hard to keep 
things simple". The authors did 
this well. I welcome a revision 
and would make a publication 
decision on their thoughtful 
responses. Thank you for the 
opportunity to participate in the 
peer review process with this 
manuscript.   
List of positives: 
 Excellent concise 
general overview of use 
of placebo surgery 
controls in RCT 
 Includes a discussion of 
the use of natural 
history "no treatment" 
control groups, in 
addition to placebo 
surgery, "real" surgery, 
and non-surgical care 
groups 
 Creation of ASPIRE 
checklist. 
 Good discussion of 
neutral members in 
discussions during the 
informed consent 
process and the 




makers) involved in 
those discussions. 
Thank you for identifying these positives. 
  
List of MAJOR negatives:  
 No discussion of genetic 
susceptibility to placebo 
- the past decade has 
yielded several dozen 
high quality studies that 
have reported several 
biomarkers indicating at 
least a moderate 
influence of genes on 
placebo response 
(COMT, OPRM1). 
R1: Unfortunately we are word restricted and whilst this is a 
very interesting and worthwhile sub area of placebo science 
we simply do not have room to do the subject justice in this 
précised review.  However, it should be commented upon and 
we have added a couple of sentences alluding to this (and 
indeed to other aspects that we may not have covered in 
depth eg. neurophysiology). 
 
We have tried to focus and outline surgical specific placebo 
aspects for this work and not become too entwined with 




Text added:  
With regard to the placebo response in general, it should also 
be noted that there is some suggestion of genetic susceptibility 
to placebo with biomarkers indicating at least a moderate 
influence of genes on placebo response 
 
 
 No discussion of the 
selection bias of 
R2: A good point and mental health/psychiatric factors for 
selection bias are indeed worth consideration.  However, 
individuals that are 
willing to be randomized 
to a placebo surgery 
without mental 
health/psychiatric 
evaluation. The same 
mental health status 
that may allow an 
individual to participate 
may be the same mental 
health status that would 
portend a worse 
outcome following any 
surgical intervention - 
this is usually an 
elevated pain state, low 
pain threshold mental 
wellness disorder. This 
cascade of decisions 
motivated by pain 
and/or dysfunction may 
alter the study's 
ultimate conclusions.  
empirical evidence from placebo-surgical studies suggest that 
patients have a variety of reasons for wishing to participate in 
a placebo controlled trial, and that they make sound and 
informed judgements when doing so.  For example, extensive 
qualitative work undertaken with prospective participants as 
part of the design of the KORAL placebo surgical trial 
(Campbell et all, Health Technology Assessment 2010; 14(5): 1-
180) suggested that the majority of all eligible patients would 
consider participating and they highlighted a range of reasons 
for wishing to take part - including an expressed desire to help 
others; perceptions about the potential personal benefit to be 
gained from participation (and not solely via the intervention 
but also through the wider trial processes).  As such, the 
empirical evidence does not suggest selection bias of this type 
is as strong as the reviewer suggests.  We have added a 
sentence to highlight that the empirical evidence suggests 
participants have varied reasons for wishing to take part in a 
placebo-surgical trial. 
 
Added text … “The idea is to achieve public buy-in by 
highlighting prestige and legitimacy, both signalling 
worthiness of the placebo design. Empirical work has shown 
that when well informed, patients can be willing to take part in 
placebo-surgical trials and highlight many positive reasons for 
doing so “ 
 –  L446-450 
 
It has been acknowledged in the literature, however, that 
patients may have different inherent beliefs and preferences 
towards surgery in general as an intervention (which may 
affect their openness, and possible response, to surgical 
interventions in general and thus, by extension, one could 
argue to the placebo effect of surgery).  This has been 
incapsulated into the validated “Beliefs about Surgery” 
questionnaire (Francis et al; Psychol Health. 2009; 
24(10):1125-37).  We have included a reference to this in the 
revised manuscript. 
 
Added text … “The wider literature has also noted that 
individuals can hold inherent beliefs and preferences about 
surgery as an intervention per se, which may consequently 
affect their willingness to participate in a placebo-surgical trial 
- although this can be measured and accommodated for 
[Francis et al,2009).”  L425-428. 
 
 Would like to see a little 
discussion on the 
balance of cost and 
financial impact to 
design, conduct, report, 
and disseminate the 
R3: Agree here but again limited in space for this interesting 
area. We have added a short paragraph. 
 
Added Text: There are many arguments around the balance of 
the cost and financial impact to design, conduct, report, and 
disseminate the findings of a placebo surgery controlled 
findings of a placebo 
surgery controlled 
randomized trial, versus 
the continued 
performance of the 
surgery in question 
without high level 
evidence. 
randomized trial, versus the continued performance of the 
surgery in question without high level evidence.  This is an 
ethical subject in itself, however, without such a study, 
ineffective surgery may continue with costs and resource 
consumption, crowding out more effective treatments, and 




 Would like to see more 
discussion on the 
geographic and cultural 
differences in patients 
that could influence a 
placebo response - 
Finland known for sisu 
and grit; Denmark and 
Norway known for 
hygge; USA known for 





R4: Within any randomised controlled trial, there are many 
known and unknown confounders that may affect response to 
treatment (and by extension to the placebo effect).  This is 
well recognised in the trial methodology literature.  Indeed, 
this is one of the main arguments in support of randomisation 
– as randomisation will ensure that all possible confounders 
are balanced across the groups.   
 
This would also apply across any cultural differences in trial 
populations – randomisation would ensure that any such 
effects (and indeed any other known or unknown effects) 
would be equalised across the groups.  We have added a 
sentence to the manuscript to note this. 
 
Added text … “Randomisation, however, ensures that any such 
confounder (and indeed any other unknown confounder) is 





List of MINOR negatives:   
 Use of "best" 
nonoperative care is 
superfluous, ambiguous, 
and unnecessary - why 
not also call it "best" 
operative care - some 
surgeons are good, 
some are bad; some 
physical therapists are 
good, some are bad. 
This "best" descriptor 
implies that the non-
surgical intervention is 
superior to something, 
while the surgery is just 
"surgery", not "best 
surgical treatment".  
R5: Agree – we have rephrased. (we mean evidence-based). 
 
Added text: 
“Non-operative care has the advantage of reflecting the real-
life alternatives (surgery versus a different type of treatment). 
The disadvantage is that it does not allow testing of any direct 
or placebo effect of non-critical aspects of the procedure, 
including patient expectations and concomitant treatments. It 




 Would like to see a 
greater discussion of the 
situation when a surgical 
R6:  It should be noted that reviews of placebo surgery 
research have shown that the risks from placebo allocation are 
lower than that of the active intervention groups, and that it is 
treatment's risks in a 
"no fidelity" or 
"low/minimal fidelity" 
placebo surgery group 
significantly outweigh 
the benefits to society - 
how does a group of 
researchers reconcile 
this issue? How much 
risk is too much? When 
is a placebo surgery 
control group trial "not 
worth it"? the example 
that immediately comes 
to mind is that of hip 
arthroscopy - the most 
rapidly growing sub-
specialty in all of 
orthopedic surgery and 
musculoskeletal 
medicine across the 
world - even a 
low/minimal fidelity 
placebo group involves a 
very significant risk - up 




obturator) due to 
traction, sex organ 
dysfunction, genital skin 
injury, iatrogenic 
cartilage or labral injury 
upon camera entry into 
the joint, peripheral 




the benefits versus the additional risk of surgery that is being 
tested in placebo trials.  This has been discussed in some detail 
already but we have added a section to enhance. 
 
Added text:  
 
“Discussion should include the situation when a surgical 
treatment's risks in a "low/minimal fidelity" placebo surgery 
group can potentially outweigh the benefits of the study 
findings to society.  This can be difficult to reconcile. It is not 
clear how much risk is “too much” and when a placebo surgery 
control group trial is "not worth it". It remains a complex area 
and will depend on individual procedure risk plus routine 
surgical risk (anaesthetic etc.) with consideration of the 






 discusses only 
musculoskeletal 
medicine, orthopedic 
surgery cases, with little 
discussion (intra-luminal 
endoscopic 
interventions) of other 
aspects of medicine.  
R7:  Reasonable point although a good section of the placebo 
control literature involves MSK and orthopaedics. 
 
Examples from chest medicine (bronchoscopy) and GI surgery 
have been added. 
 
L293-298 
 No discussion of clinical 
decision-making in the 
situation of a patient 
We were not entirely sure what the reviewer was asking for 
here and in the interests of word count have not addressed 
this point. 
with "failed non-surgical 
treatment and 
continued symptoms" 
and published data 
showing placebo 
surgeries (and, of 
course, the active "real" 
surgery too) improve 
symptoms. 
 No discussion of 
Hawthorne effect in a 
research design like this 
R8: We have inserted new text to briefly raise the issue of the 
Hawthorne effect.  The inserted text as follows: 
“A change in outcome may still be observed in a no 
intervention arm for various reasons (such as a Hawthorne 
effect and regression to the mean), which will also contribute 
to the observed effect in all groups. Nevertheless, the absence, 
or the presence of only a modest difference in the observed 
effect between surgery and no intervention would cast serious 





 Lack of consideration 
that a "no fidelity" (i.e. 
sham surgery) placebo 
surgery control is not 
truly "no fidelity", as 
skin incisions alone can 
denervate (for example, 
tennis elbow placebo 
surgery trial in Australia) 
and have a real 
physiologic effect and 
reduce pain. 
R9: Thank you. We agree with this point and have modified 
the text and Table 2 accordingly.  The concept and position of 
NO fidelity has been removed and the position of sham 
treatment clarified. 
 
L168-176 (and Table 2) 
 
 Lack of consideration 
that a "minimal/low 
fidelity" (placement of 
arthroscopic camera and 
turn on fluid) placebo 
surgery control is not 
truly "low fidelity", as 
the introduction of 
saline lavage can 
remove inflammatory 
mediators, improve joint 
homeostasis, and 
improve the joint milieu.  
R10: Agree with reviewer… (to some extent).  The capability to 
identify the theoretical “critical surgical element” of the 
surgery can indeed pose some difficulties in defining “fidelity” 
of the placebo intervention to the surgery (such as in the case 
given).  However, that said, there is nearly always a more 
concrete theoretical basis and justification of the surgery than 
just “the introduction of saline lavage to remove inflammatory 
mediators to improve joint homeostasis, and improve the joint 
milieu”.  It is unlikely surgery would be sanctioned and 
performed with this as the primary purpose. A line has been 
added to account for this issue but we do not wish to confuse 




Added text:  
 
“It should be noted that this working framework is dependent 
on the theoretical premises of the operation and postulation of 
a “critical surgical element”.  This is not always possible, 
especially with surgeries that create effect by a multi-modal or 
dependent set of procedures.” 
 
 




evaluation of the quality 
of the surgeries 
performed. If efficacy 
design in a homogenous 
sample, then that "can it 
work" mandates the 
best surgeons, similar to 
your use of "best non-
operative care".  An 
evaluation of surgical 
quality of all surgeries 
performed would 
validate the techniques 
used.  
R11: This is an interesting point and placebo control trials 
should not reflect a heavily pragmatic design.  If information 
on mechanism is required (and mostly it is from these studies) 
then the surgery should have a definite minimum quality and 
be performed by experienced surgeons.  We have stated this 




The issue of quality control also arises for the surgical 
procedure. If information on mechanism is required (and it 
mostly is from these studies) then the surgery should have a 
definite minimum quality and be performed by experienced 
surgeons. The “can it work" question tends to trump the “does 
it work” question and this mandates the use of highly 
competent surgeons. Evaluation of surgical quality of all 
surgeries performed in such studies may be needed for 
validation. 
 
 No discussion of blinding 
index, in which patients 
may be able to 
determine their group 
allocation prior to study 
completion. 
There are very mixed views in the literature on the 
appropriateness of using the blinding index.  The CONSORT 




BMJ.pdf) also stresses the methodological difficulties with 
such testing of the “success” of the blinding and do not 
advocate that it be done.  It notes “Because participants and 
healthcare providers will usually know whether the participant 
has experienced the primary outcome, this makes it difficult to 
determine if their responses reflect failure of blinding or 
accurate assumptions about the efficacy of the intervention. 
Given the uncertainty this type of information provides, we 
have removed advocating reporting this type of testing for 
blinding from the CONSORT 2010 Statement.”   
 
Given this wider ongoing debate about the appropriateness 
(or not) of testing for blinding, we would prefer not to stray 
into the discussion of testing/not testing for blinding in this 




Line by line analysis:  
 Abstract: 
 P2:  
 Well written, concise. 
Directly states the 
purpose of the 
submitted review.  
Thank you 
   
 Introduction and 
Background: 
 P2:  
 Briefly discusses reasons 
for impetus of the 
review. Well done. 
Thank you 
   
 What is a "placebo" in 
the context of surgical 
trials? 
 P4: for clarity for the 
reader, the penultimate 
and final paragraphs of 
this section contradict 
Table 2 - in the text, 
sham is "low fidelity". 
However, in Table 2, it is 
"no fidelity". Please 
resolve.  
Thank you. Amended.  See R9.  We have virtually omitted the 





   
 When are placebo 
surgical controls 
acceptable? 
 P7:  
 Unsure why 
nomenclature of "best" 
nonoperative care, 
which is actually used 
twice in the same 
sentence), is used - the 
implication to surgery is 
ambiguous and 
misleading. If we are 
using adjectives to 
qualitatively subjectively 
describe treatments, 
then why don't you call 
it "best" operative care - 
there are good and bad 
surgeons, just as there 
are good and bad non-
surgical physicians, 
physiotherapists, etc. 
Either remove "best" 
Response as above.  Addressed. 
 
L327-328 
from this section (and all 
other sections similarly 
used), or add the same 
descriptor the surgery 
groups.  
   
 Trial conduct issues for 
placebo surgical trials 
 P9: would be helpful for 
the reader to discuss 
potential selection bias 
upon willingness to be 
possibly randomized to 
the placebo group, 
despite complete 
educated informed 
consent process. The 
innate thought that the 
patient may not receive 
any benefit, and could 
potentially have a 
complication (morbidity, 
mortality, adverse 
event), in most normal 
able-minded adults, for 
the potential benefit of 
society, precludes 
participation. Thus, 
those that do participate 
may be of different 
stage in mental 
wellness. It is very well 
known that psychiatric 
wellness is a critical 
perioperative issue, as 
individuals with mental 
health disorders do less 
well following most 
elective surgical 
interventions. Similarly, 
pain can have significant 
effects on mental 
wellness. Pain can 
Response as above. In R2. 
influence trial 
participation decision 
making for patients. At a 
minimum, a 
demographic statistical 
comparison of the two 
(or more) groups 
(enrolled and 
randomized versus 
declined for standard 
care). 
 Similarly would be 
helpful to briefly discuss 
genetic analysis for 
propensity to respond to 
a placebo surgery 
(COMT, OPRM-1, CB1, 
CB2, TPH2, 5HTTLPR, 
among several other 
known biomarkers). 
Although randomization 
should mitigate the 
possible distribution of 
all placebo responders 
in one group and none 
in another group, it can 
still happen - and 
without measurement 
of these characteristics, 
the true placebo effect 
is unknown. 
Response as above for R1. 
  
 Interpretation and 
translation into change 
of policy and practice 
 P10: last sentence of the 
page - "advice for 
patients" - please add 
further context - if there 
are only two study arms 
- one placebo surgery 
and one "real" surgery, 
without a natural history 
"no treatment" model, 
and the patient has 
already tried non-
surgical care and is still 
significantly 
symptomatic, what do 
you do? How do you 
manage that clinical 
encounter? The patient 
doesn't care what you 
do in the operation, they 
just want to feel better. 
Thus, if a "real" or if a 
placebo surgery works, 
that's all they care 
about. How do you 
reconcile this issue? 
R12: This is a useful point but perhaps steps outside the remit 
of the work.  We have added the following for completeness: 
 
Added Text: Advice for patients should include information 
about the likely benefits of both the definitive and alternative 
treatments. This paper has not addressed the [controversial] 
merits of offering placebo treatment (surgery) as a definitive 
intervention. Such an option is only possible if there are 






 Only 15/45 are within 
past five years. 
We note this comment, but wished to include many of the 
seminal papers in the field, many of which were published 
more than five years ago. 
  
REVIEWER #2:  
Beard and colleagues present a 
review on the use of placebo 
control in surgical trials. The 
manuscript is structured into the 
following sections: (i) 
introduction; (ii) definition of 
placebo in this context; (iii) 
acceptability of placebo; (iv) risk; 
(v) trial conduct issues; and (vi) 
interpretation. The main 
message is that placebo-
controlled trials on surgical 
Many thanks for a set of well thought out suggestions and 
comments. 
interventions may be justifiable 
in some situations and that the 
degree of fidelity to the 
investigational surgery is an 
important consideration. A 
checklist is included to help with 
design of such trials. 
 
The topic is of interest and the 
issues addressed are ethically 
complex and not easy to resolve. 
The paper is generally well 
written. I have the following 
comments: 
 
1. The issue of equipoise is 
arguably central to the 
consideration of 
whether or not a 
placebo control is 
justifiable. In this 
context, brief discussion 
about the complexity of 
establishing equipoise 
would be germane to 
the discussion. The 
paper of Miller et al. 
provides extensive 
discussion on the 
problem of agreement 
in relation to what 
constitutes equipoise 
(Miller FG, Joffe S. 
Equipoise and the 
dilemma of randomized 




We agree that equipoise is one of the key issues in the ethics 
of placebo RCTs in surgery. We now emphasize this point:  
Added text: “Ethical standards suggest, however, that 
exposing research participants to such risks is allowed provided 
equipoise exists among the study arms, study harms have been 
minimised and are acceptable to the participant.” Miller and 
Joffe (2011) take the view that equipoise would not permit 
placebo RCTs when a surgical procedure is in common use. 
Hey et al. (2016) argue that this misconstrues equipoise, 
because the relevant uncertainty is the state of evidence, not 
opinion or practice. We have added this important 
clarification, saying that “Disagreement or uncertainty should 
be understood in terms of the state of evidence rather than 
unsubstantiated opinion.” And with regard to examples such 
as vertebroplasty, “Although the surgical procedure is 




2. The central ethical issue 
to be considered from a 
patient perspective 
relates to the degree of 
risk that the patient is 
exposed to. In contrast 
to placebo-controlled 
medicines trials (where 
the main risk is that the 
patient does not receive 
the active treatment and 
no or minimal risks are 
expected from the 
placebo tablet per se), 
R14 
We agree with the reviewer that the assessment of scientific 
value is key to the ethical analysis and have added a 
description of a systematic approach to the assessment of 
value and validity by Binik and Hey (2019). We now say: Added 
text: “Research ethics committees commonly struggle with the 
assessment of scientific value, and use of the “value-validity 
framework” is recommended. The assessment of scientific 
value requires that (1) the research question is clinically 
important, (2) the hypothesis is justified by the current state of 




the patient is exposed to 
a definable and 
foreseeable degree of 
risk due to the "sham" 
procedure, without any 
prospect of benefit for 
the individual. In this 
respect, only the greater 
societal value can 
compensate for the risk 
assumed at an individual 
patient level. This issue 
requires more attention 
and is a critical element 
of informed consent. For 
example, more detailed 
discussion of 
mechanisms to evaluate 
the "social value of the 
study" should be 
provided. 
3. By considering patients' 
preference in the study 
design, it may be 
possible preferentially to 
enrol patients who are 
actively demanding a 
surgical therapy. This 
issue might be explored 
and discussed. 
R15: A reasonable point.  This pre-existing bias might exist.  
Such a feature would not be present when there is a non-
surgical or no treatment comparison required.  Again with 
limited space we have not included substantial changes at this 
time (but modified the wording).  If the Editor wishes this to 
be addressed in more detail we can include but such 
discussion may be substantial. 
 
L425-429 
4. Against the background 
of the complex ethical 
issues at hand, in these 
types of trials, it is 
particularly important 
that the clinical trial has 
the greatest possible 
chance to answer the 
primary research 
question in a robust 
manner (high internal 
validity) with high 
generalizability for the 
relevant clinical 
community (high 
external validity). This 
should be emphasized in 
the discussion. 
R16: Agree.  We believed we had addressed this but there was 
room for amplification.  We have added to the key message. 
 
Added Text: 
Against a complex set of ethical issues, it is particularly 
important that these trials have the greatest possible chance 
to answer the primary research question in a robust manner 
(high internal validity) with high generalizability for the 
relevant clinical community (high external validity) 
 
L528-531 




We thank the reviewer for this point. We are unaware of any 
guidance and would welcome specific suggestions. We believe 
boards are faced with 
the challenge of 
weighing the 
foreseeable and 
preventable harm of a 
placebo procedure 
against the risk of 
mistakenly believing an 
invasive procedure or 
implant to be useful 
when it is actually not. 
Are there any specific 
guidelines for 
institutional review 
boards dealing with this 
issue? Perhaps detail 
could be included if 
available. 
that the possibility of therapeutic misconception is best 
addressed through evidence-based changes to the informed 
consent process that have been shown to improve research 
participant comprehension. First, placebos must be clearly 
identified as lacking evidence -based prospect of direct benefit 
and language that may unwittingly mislead participants must 
be avoided. Second, consent forms should be simplified and 
adequate time for one-on-one discussion provided. Third, 
research participant comprehension should be judged as 
appropriate. We have now added language emphasizing that 
[added text]  
 
Added text:  
As placebo surgical trials provide a potentially nontherapeutic 
intervention additional protections may be indicated. It is 
important to ensure adequate patient comprehension of the 




6. The authors suggest that 
the placebo effect can 
be mediated by 
conditioning and 
response expectancy. A 
third factor, experience 
of the health care 
interaction itself, has 
also been identified as 
contributing to placebo 
effect and might be 
mentioned (Jubb J, 
Bensing JM. The 
sweetest pill to swallow: 
how patient 
neurobiology can be 
harnessed to maximise 
placebo effects. 
Neurosci Biobehav Rev 
2013;37(10 Pt 2):2709-
20; and Di Blasi Z, 
Harkness E, Ernst E, 
Georgiou A, Kleijnen J. 
Influence of context 
effects on health 
outcomes: a systematic 
review. Lancet 
2001;357(9258):757-62). 
An initial draft (and the accompanying NIHR report) contained 
greater neurobiology and more detailed descriptions of 
conditioning.  However, once again in view of word limit and 
reference limit it was decided this might not be seminal to 
guidance for researchers setting up, conducting and reviewing 
placebo trials in surgery (one of the main purposes of this 
paper). We have omitted in this particular work but will 
include more in the NIHR MRC report. 
7. The authors may wish to 
include mention of the 
Hawthorne effect in 
Response as above (to point raised by referee 1 about 
Hawthorne) – R8. 
relation to its potential 
to impact on outcomes 
in both investigational 
and treatment arms 
(Sedgwick P, Greenwood 
N. Understanding the 
Hawthorne effect. BMJ 
2015;351:h4672). 
8. It might be illuminating 
to mention and discuss 
the ORBITA trial (Al-
Lamee et al., Lancet 
2017) in the paragraph 
relating to identification 
and mitigation of risk. 
This trial has many 
similarities with a 
placebo-controlled trial 
of surgical interventions, 
and might be a useful 
reference for the reader 
with a surgical 
background. Although 
the primary results of 
that trial have received 
widespread attention 
from many stakeholders 
involved in that field (in 
line with the issues 
mentioned in the 
section on 
interpretation and 
translation on page 10), 
analysis of serious 
adverse events, shows 
that these were 
considerably higher in 
the placebo or sham-
controlled arm (8 events 
vs. 0 events, see data in 
supplementary material 
of that trial). 
R18 
Sensible addition for balance.  Now included. [Added text] 
 
This issue is highlighted by trials such as the ORBITA study in 
interventional cardiology. The placebo group were in this case 
found to have a greater number of adverse events than the 





9. It would be useful to 
include a text box 
indicating the methods 
that were used in 
searching the literature 
for the present 
manuscript. 
R19: Completed and added. 
 
The methods used to search the literature are reported fully in 
paper reporting the systematic review update, which is 
currently accepted with minor revisions by the Journal of 
Clinical Epidemiology. We include a summary of these 
methods in the attached text box with reference to the full 
paper. It is expected the paper will be accepted fully by the 




10. Assessment of the 
success of blinding is 
essential in trials with 
placebo control. This 
issue should be 
mentioned and relevant 
citation included. 
Response as above (re measuring blinding via blinding index 
raised by reviewer 1).   
11. Additional detail should 
be provided for the 
reviewer on the 
systematic review that 
was conducted. It is not 
helpful to refer the 
reader to a paper that is 
in preparation. In my 
opinion, at least an 
appendix table listing 
the included studies and 
their characteristics 
should be provided as 
supplementary material 
to the present paper. 
R20: This has been provided. 
 
As above, we have now had the paper reporting the 
systematic review in full accepted with minor revisions by the 
Journal of Clinical Epidemiology. It is expected that the paper 
will be accepted fully by the end of November 2019. We now 
include an appendix table listing included studies and their 




REVIEWER #3  
Name: Teppo Järvinen  
Position: Professor of 
Orthopedics and Traumatology 
 
  
Comments for the Authors 
Thank you very much for asking 
me to review this interesting 
paper entitled: "Considerations 
and Methods for Placebo 
Controls in Surgical Trials: State 
of the Art Review and ASPIRE 
Guidance".  
The objective of the paper - to 
provide a summary of current 
knowledge on placebo controls 
in surgical trials - is a very 
interesting one and of utmost 
importance/interest to the 
entire surgical discipline at large. 
Of all surgical disciplines, 
orthopaedics is probably the one 
that has been most affected by 
the increased popularity of this 
Many thanks for your detailed and highly considered 
comments.  It is clear a considerable amount of time has been 
spent on this review (actually by all reviewers) and the 
expertise in this area is very evident. 
trial design. A seminal paper 
published in 2002 (Moseley, 
O'Malley et al. 2002), assessing 
the efficacy of arthroscopic 
debridement for knee pain in 
osteoarthritic patients, pushed 
the entire field of orthopedics 
into turmoil: Using a placebo-
surgery controlled design, the 
authors provided 
unprecedentedly robust 
evidence that questioned the 
viability of this enormously 
common orthopedic surgery. 
This brought along a realization 
that not all of our clinical 
practices - although being 
intuitively highly rationale - 
stand the scrutiny of robust 
scientific testing. The trial and its 
findings also prompted a major 
revolution in the way we now 
test our practices, as a 
considerable number of our 
popular procedures only have 
low quality (high risk of bias) 
evidence - at best - to support 
the practice.  
Undoubtedly, the group 
gathered for the task of 
developing the guidance 
possesses the experience and 
knowledge to provide a premier 
scientific contribution on the 
topic.  
I have now spent quite a 
considerable amount of time to 
thoroughly review the paper. 
Below please find my 
comments.  
  
MAJOR COMMENTS  
Having been involved in the 
design and execution of three 
placebo-surgery controlled 
trials, my major intellectual 
challenge has always been - and 
after reading this paper, still 
remains - the question as to 
what is the primary purpose of 
these placebo-surgery 
R21: This is an insightful point, has been the point of much 
discussion and many of the group do have some sympathy. 
 
First, it is felt we are in agreement about the purpose being 
the evaluation of surgery (taking account of the placebo 
effect).  There is no attempt to include the evaluation of the 
effect of placebo (hence the reduced neurobiology aspect).  
This has been further emphasised in the draft.  
 
controlled trials? The authors 
start their paper (1st sentence of 
the abstract) by saying "… 
assessing the efficacy of surgical 
interventions". My take on the 
question is exactly the same: 
Placebo-surgical trials should be 
restricted for this purpose, only. 
However, when reading through 
the paper, I can't help to think 
that the authors seem to be 
suggesting that these trials can 
(should) also be used to study 
the potential "placebo effect" of 
surgery - an assertion that stems 
from their desire to include a 
"no treatment" group. Such 
desire is obviously both highly 
scientifically ambitious and 
intuitively rationale, but in my 
opinion, has two fundamental 
flaws that… have convinced me 
to abandon the idea. Namely: 
In regard to 2 or 3 group designs, and inclusion of a no 
treatment group – we have already included a section on this 
(Should a placebo-surgical trial have a no intervention arm) 
but the points raised may require some minor adjustment 
(which have been completed). 
 
The main issue here is whether demonstration (using a 2 arm 
study – placebo v normal surgery) that the mechanism by 
which the surgery was thought to provide effect is proven 
wrong, and that this evidence is then sufficient to make 
inferences about lack of benefit for surgery overall. There is a 
difference of opinion here (particularly by surgeons) and some 
feel that the benefit of surgery should be evaluated outside 
the known mechanism (i.e. a “black box” effect approach can 
sometimes be acceptable). 
 
For example in a 3 arm placebo control trial, (which includes a 
no treatment arm), the comparison (and lack of effect) 
between any kind of surgery (placebo or normal) is often more 
informative than the comparison between the two surgeries.  
 
A comment in response from one of our co-authors is helpful. 
 
“I do sympathise to some extent with this reasoning, as I voiced 
during the Oxford meeting.  
 
In addition, these trials usually have to be done with ‘academic’ 
funding support and within ‘academic’ resources. There’s a 
considerable difference in resources and time needed between a 2-
armed trial and a 3- or 4-armed trial. The latter may be ‘scientifically’ 
superior, but are they always needed?  
 
Perhaps a few words could be added on when 3- or 4-armed 
trials are really needed?”. 
 
In view of the contention and this sensible course, a few lines 





1) Can we realistically assume to 
be able to carry out a placebo-
surgical trial with a "no 
treatment group" and expect 
the findings of this particular 
group to be robust enough to 
truly quantify the placebo effect 
(and thus, justify its inclusion in 
the design), given that patients 
randomized to this group should 
be as symptomatic as those 
This point is well made but examples have shown that patients 
are willing to be randomised to a 3 group trial – CSAW, KORAL 
… probably others.   
 
Re KORAL – no issues were raised by patients about the no 
treatment group (it was called “non-operative management 
with specialist re-assessment”) – they were happy to be 




randomized to placebo surgery 
or the index surgery? In the end, 
as a surgeon, I have been 
trained to consider surgery the 
last resort after all other 
(nonoperative) means have 
failed. Under such 
circumstances, I find it hard to 
believe that highly symptomatic 
patients would be willing to sit 
back and wait for a period long 
enough to first be able to 
arrange and carry out the 
surgeries in the other groups 
and then also have a sufficiently 
long period of time for follow-up 
to obtain full recovery after 
surgery (which is the absolute 
necessity for robust inferences). 
Unless these premises are met, 
the inclusion of a "no treatment 
group" threatens to compromise 
the validity of the findings of the 
entire trial. 
We believe the CSAW is an example where, while there were 
challenges associated with conduct and interpretation of the 
no treatment arm, its inclusion added value to the study 
overall and of the wider interpretation. The value of such an 
arm would likely be context specific and to an extent only 
assessable after the study has been completed.  We have said 
this in the text but amplified. 
 
See R21 above and in text. 
 
  
Also, there is another, equally 
troubling issue regarding the "no 
treatment group", that is 
blinding (lack of it). Both the 
patients and the researchers 
may have different and even 
disproportionate expectations of 
benefit with regards to the 
different study treatments. In 
fact, it has even been speculated 
that when patients are told at 
entry about the possibility of 
surgical treatment but then 
allocated to non-operative or 
even "no treatment", so called 
'failed opportunity' may make 
patients with residual symptoms 
less satisfied with their care and 
subsequently drive them to seek 
surgery (Dowrick & Bhandari 
JBJS-Am 2012).  
R22: This point, also dealing with the two arm or three arm 
issue is also valid.  A sentence on resentful demoralisation has 
been added. 
 
However, that said the “no treatment” arm has multiple 
purposes.  We have added text as noted above which 
highlights other effects which a no treatment group will also 
undergo which may result in an observed change in outcome 





Finally, I find it quite irrational 
that we first claim that the use 
of a placebo surgery comparator 
(vs. any other design) is 
As above and see response below R23: 
mandatory in order to 
adequately mask the patients, 
caregivers, outcome assessors, 
etc., and then we will 
immediately abandon this 
principle in asserting that lack of 
blinding does not compromise 
the validity of the comparisons 
between "no treatment" vs. 
other groups? To me, this is a 
circular argument, and as such, 
an intellectual fallacy but 
perhaps the authors are able to 
explain why my assertion is not 
valid. At least this part of the 
paper needs better justification.  
  
To showcase the above noted 
concerns, please allow me to 
use the only (?) trial that has set 
out to assess/quantify the 
surgical placebo as an example 
(the CSAW trial addressing the 
efficacy of subacromial 
decompression surgery, ref. #24 
in the original submission) In this 
study, the investigators 
randomised 313 patients to 
three treatment groups: 106 to 
decompression surgery, 103 to 
arthroscopy only, and 104 to no 
treatment. Perhaps due to the 
imminent risk of high incidence 
of crossover from the "no 
treatment" group, the 
investigators chose 6 months as 
their primary outcome 
assessment timepoint. Due to 
this methodological choice, 24 
[23%], 43 [42%], and 12 [12%] of 
the decompression, arthroscopy 
only, and no treatment groups, 
respectively, did not receive 
their assigned treatment by 6 
months (at the primary outcome 
assessment timepoint!). And 
further, >10% of those initially 
allocated to "no treatment" 
ended up having surgery by the 
6-mo follow-up. As showcased 
by this study, many - if not all - 
R23: Crossover was indeed a negative issue with CSAW but 
this was considered against the merits of having the no 
treatment arm.  Some of the authors (of this work) would 
indeed like to indulge in further detailed discussion of this 
particular trial (positive and negative) but other reviewers 
have suggested more balance in terms of speciality and study 
is required.  We have aligned with the latter. 
 
However, we have added a sentence to address the main 
excellent point raised. 
 
L352-355 
of the concerns expressed above 
materialised. As laudable as the 
effort by the CSAW investigators 
was from a scientific 
perspective, one needs to 
critically assess the true 
implications of the findings. 
Perhaps this paper provides a 
perfect venue for such thorough 
elaboration. 
  
2) Is it (ethically) justified to use 
placebo-surgery when there is 
already evidence to suggest that 
the index surgical procedure is 
no better than the best 
nonoperative treatment? Or do 
we require that surgery has 
"proven" superiority, but the 
evidence is questionable due to 
high risk of bias (low quality)? 
When looking back, quite a high 
percentage of previous placebo-
surgery controlled trials (at least 
in orthopaedics) have been 
carried out under the 
circumstances that we have 
already had evidence to suggest 
that the studied surgical 
procedure is no better than the 
(best available) nonoperative 
treatment. Or at least the 
clinical meaningfulness of the 
alleged superiority/benefit is 
highly debatable. Should we still 
consider placebo-surgery design 
justified under such 
circumstances? One argument in 
favour of still being proceeding 
to carry out a placebo-surgery 
controlled trial is that surgery vs. 
nonoperative treatment trials 
are inherently of "low quality / 
high risk of bias" (although the 
bias, if surgical placebo effect 
does exist, should also skew the 
data in favour of surgery). 
Another similar argument would 
be that more robust evidence is 
required as the clinical practice 
still continues "unabated" 
A complex philosophical point - which probably cannot be 
done justice with the available word count. 
 
In response to the reviewer; the main issue here is that many 
surgical procedures in general have been adopted and become 
common without adequate evaluation. Note we are trying 
hard to address this, particularly with new interventions 
coming on stream i.e. robotic surgery, AI. but still lag behind.  
The “power” of surgery (and ironically this is closely linked to 
its strong placebo effect) make any withdrawal of treatment 
difficult without evidence from influential and robust studies 
(such as FIMPACT and CSAW). 
 
If there is high quality evidence that surgical treatment is no 
better than non-operative treatment then absolutely no 
placebo trial is required. 
 
These issues are important and fascinating but maybe more 
political and outside the science reported here.  
 
We would respectfully request the editor to make a decision 
whether this particular area should be expanded.  We are 
happy to do so but have already extended word count 
addressing many of these interesting points. 
 
despite the evidence 
questioning the particular 
practice. 
This brings me to my only other 
comment regarding the 
manuscript: The authors note "a 
long lag between evidence 
becoming available to a 
significant change in practice" 
on page 10, in the paragraph 
beginning "Experience with…". 
However, their knee arthroscopy 
example might not be 
completely accurate, as we have 
witnessed quite a dramatic de-
implementation of knee 
arthroscopy (in a range of 50-
70% from the highest volumes) 
in many countries, such as 
Finland, Sweden, Norway, 
Denmark, the Netherlands, and 
even the US. Strictly speaking, 
the trial by Moseley et al. (NEJM 
2002) showed arthroscopic 
debridement futile in patients 
with advanced OA - most 
patients undergoing knee 
arthroscopy are treated with 
arthroscopic partial 
meniscectomy (APM, a 
completely different procedure) 
and have early knee OA. 
Therefore, a clear medical 
reversal may not have been 
required until the publication of 
a series of other trials proving 
APM futile, which took place 
between 2011-2017.  
R24: We agree the evidence for implementation (with hard 
data) is not strong. However, it has taken some time for 
arthroscopy for OA to become considered inappropriate.  The 
real point being made is that there is often resistance to 





4) Ethics: Page 3, second para.: 
"Some information on the 
ethical implications of surgical 
placebo trials is available 7- 12." 
I respectfully feel compelled to 
state that this sentence 
undermines the prior ethical 
analyses on the use of placebo-
surgery, which - at least to me - 
are quite exhaustive and quite 
thoroughly address many of the 
ethical dilemmas related to the 
use of the design. I have 
particularly found the work by 
Franklin Miller useful, so 
perhaps in addition to ref. #11, 
the authors should consider 
adding this reference (Miller FG. 
Sham surgery: an ethical 
analysis. Sci Eng Ethics 
2004;10:157-66) as according to 
my understanding, this is the 
very first paper that outlines the 
"6 key ethical question" 
procedure/protocol that should 
be carried out to ensure that the 
(placebo-surgery controlled) trial 
designed is ethically sound. In 
essence, I think it would only be 
fair to give credit to those that 
have truly pioneered the field. 
And perhaps even consider 
adding this set of key ethical 
question in the paper (re: Page 
5, "a two-step ethical analysis") 
and figure 1? 
See R13 and R14:  Absolutely not our intention to exclude 
previous relevant work – indeed the work of Miller was very 
influential in our discussions.  The ethics group have addressed 
this above is response to other reviewers. 
 
We thank the reviewer for drawing our attention to this 
omission. We have added reference to this important article. 
Miller’s work, including the six key ethical questions, informed 
our discussions, and we do cover the issues addressed by his 
questions. We diverge from Miller’s project in two ways. First, 
we believe equipoise is central to the question of the ethical 
permissibility of placebo trials in surgery and argue that it 
permits important RCTs to proceed (Savulescu et al. 2016; Hey 
et al. 2016). Second, following on early work in the field 
(Weijer, 2002), we view the surgical placebo as a complex 
procedure, and this idea is foundational to our novel ethical 
analysis. 
  
MINOR COMMENTS  
  
1) Page 3, bottom of the page: 
"Any imbalance in the tone and 
quantity of information given 
about the benefits of the index 
procedure compared to that 
given for the placebo control can 
be stark and can influence 
outcome 19." 
I am inclined to think that any 
imbalance in the 
way/tone/whatsoever given 
between any two treatment 
Thank you for highlighting. Probably yes, retain this piece.  
There have been historical examples where the consent or 
Patient Information Sheet may not be optimal and 
unbalanced. We want to emphasise this point for those 
starting out in placebo surgical trials.  
groups can influence the 
outcome of any trial. Isn't this 
why patients should be explicitly 
informed about all the 
treatments, their anticipatable 
benefits and harms, etc.? Is this 
sentence truly needed? 
2) Page 4, 1st sentence after the 
title "WHEN ARE…": "Surgical 
placebos may be most 
appropriate where the benefits 
of surgery are not life-saving,…" 
I have a difficult time 
understanding this sentence, as 
it - in my opinion - implies that 
the surgical procedure 
"excluded" are those proven to 
be life-saving…? Perhaps this 
should be rephrased to state, 
e.g., "Surgical placebos may be 
most appropriate where there is 
poor evidence on the efficacy of 
the procedure and a justified 
concern that the results of an 
open trial would be associated 
with high risk of bias. 




3) Page 7, 2nd para.: "For 
interventions which may have a 
significant placebo effect a 
guideline producer would like to 
see robust studies which explore 
that effect (such as a three arm 
study comparing active 
intervention, placebo, and usual 
care - discussed below)." 
Frankly, I don't understand the 
rationale behind this comment. 
Why would a guideline producer 
want/need exploration of a 
possible placebo effect, as long 
as there is robust evidence to 
show that the index surgery is 
clinically meaningfully superior 
to both placebo and best 
nonoperative care. See also 
MAJOR COMMENTS. 
R26. Agree: We have rewritten the paragraph (and have 
provided associated references) to more clearly indicate why 
guideline producers, such as the UK National Institute of 
Health and Clinical Excellence, specify why they wish to see 
the exploration of the placebo effect.  The re-written text is as 
follows …[changed text] 
 
“Often guideline producers want to understand how a health 
gain is generated, and often feel uneasy when a gain is mainly 
generated through a non-specific placebo mechanism rather 
than the anticipated anatomical, physiological and 
psychological processes that the intervention’s logic model 
may suggest. This is particularly important where a placebo 
effect may only exist because of a trial [Ernst]. For 
interventions which may have a significant placebo effect a 
guideline producer would like to see robust studies which 
explore that effect (such as a three arm study comparing 
active intervention, placebo, and usual care – discussed 
below). This enables them to explore any placebo effect which 
may inform the guidelines produced, will help inform a payer's 
decision whether to reimburse a treatment, and suggest 





4) Page 7, next section entitled: 
"Should a placebo-surgical trial 
have a no intervention arm?" 
See my previous question and 
MAJOR COMMENTS. 
Also, "A no intervention arm has 
the advantage of measuring the 
natural history of the condition 
without any treatment." 
Unfortunately, I beg to differ. As 
noted above, this group 
(comparison to surgically 
treated groups) is compromised 
by a myriad of potential biases. 
Response as per above on no treatment (R21). 
  
5) Page 7-8, re: risks: Perhaps 
the authors should also consider 
adding a brief notion that unless 
a sufficiently robust trial is 
carried out and the surgery 
continues unabated, all patients 
are subjected to all risks related 
to the procedure. In this 
situation, the more risky the 
procedure, the more urgent the 
need for a sufficiently robust 
(placebo-surgical) trial. 
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